

## **THE UROLOGY FOUNDATION**

### **TRUSTEES' REPORT AND FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 31 DECEMBER 2024**

CONTENTS

STATEMENT FROM THE CHAIR AND CHIEF EXECUTIVE..... 3

OBJECTIVES AND ACTIVITIES ..... 5

A YEAR IN VIEW..... 7

ACHIEVEMENTS AND PERFORMANCE IN 2024 ..... 7

FINANCIAL REVIEW ..... 23

STRUCTURE, GOVERNANCE & MANAGEMENT ..... 28

REFERENCE AND ADMINISTRATIVE DETAILS ..... 30

TRUSTEES’ & DIRECTORS’ RESPONSIBILITIES IN THE PREPARATION OF FINANCIAL STATEMENTS ..... 31

REPORT OF THE INDEPENDENT AUDITORS ..... 32

STATEMENT OF FINANCIAL ACTIVITIES ..... 35

BALANCE SHEET ..... 37

CASHFLOW STATEMENT ..... 38

NOTES TO THE FINANCIAL STATEMENTS ..... 39

## STATEMENT FROM THE CHAIR AND CHIEF EXECUTIVE

People diagnosed and living with urological cancers and conditions seek information, support and interventions that enable them to get the help, support and care they need to navigate the challenges of everyday life. The Urology Foundation is the only charity in the UK representing the entire spectrum of urology health and disease through our investment in world class research, training and education programmes for our urology community and allied healthcare professionals, campaigns to raise public awareness and commitment to driving policy change.

Building on the many achievements of 2023 we set out an ambitious and exciting programme for 2024. Thanks to the support and commitment of our stakeholders, including the scientific and clinical community, nurses and allied health professionals, patients and their families, volunteers, decision makers and influencers, charity and industry partners and our generous supporters, we have achieved so much. Highlights include:

- The launch of our new five-year Research Strategy '**Improving urology health: transforming lives through research**' which aims to significantly accelerate the progress of urological research, to advance knowledge, to invest in our scientific and medical communities and, guided by research outcomes, to drive change.
- The expansion of our research portfolio, training and education programme, study and travel awards and career development opportunities to support our urology community and allied healthcare professionals. We were pleased to appoint our first Grants Executive & PPIE (Patient and Public Involvement and Engagement) Lead to support this busy programme.
- A three-year grant to the TUF Trials Unit (TTU) - our partnership with the Centre for Healthcare Randomised Trials (CHaRT) at Aberdeen University. The TTU aims to identify and support promising research ideas in urology, mentoring and developing the next generation of urological surgeon trialists, and promoting best practices within the urological community.
- A commitment to driving change in Urinary Tract Infections (UTIs) which has seen the launch of a dedicated UTI Research Grant call totalling £250,000, a Nurse-led UTI Information Service and Helpline, training and resources for healthcare professionals. TUF was invited to become a partner on the James Lind Alliance (JLA) Chronic and recurrent urinary tract infection Priority Setting Partnership (PSP).
- The launch of a new Communications Strategy to raise awareness of urology health and the work of The Urology Foundation, drive change in urology care and practice through our policy work, campaigning and health awareness initiatives and strengthen our partnerships. This has seen the launch of a new website, engagement with parliamentarians and decision makers including our "Urology Pledges" manifesto to coincide with the General Election, expanded media relations and campaigns.
- Ensuring people affected by or at risk of urological disease have the opportunity to be heard, to influence and drive change through our PPIE Programme, campaigning and advocacy, media engagement, services and resources.
- Our campaigning and advocacy work particularly in the areas of prostate cancer, UTIs and bladder health.
- Investment in our fundraising programme: dedicated resourcing, an enhanced events programme and the development of a Fundraising Appeal to support the delivery of our new Research Strategy.

Our success and achievements would not have been possible were it not for the efforts and commitment of so many people and the generosity of our wonderful supporters. Sincere thanks to all those who have supported us and contributed to the many achievements of 2024.



**Mary Garthwaite, Chair**



**Rebecca Porta, CEO**

## OBJECTIVES AND ACTIVITIES

The Urology Foundation's objectives are to:

"Advance, promote, encourage, develop and improve the study and knowledge of urology, urological surgery and the general knowledge of science and medicine and all matters relating to the progress and development of that branch of science and medicine and for that purpose to fund, aid, maintain and endow scholarships, fellowships, chairs and bursaries and generally to assist in the funding, instruction and support of persons and institutions engaged or involved in urological research work."

## OUR VISION AND MISSION

We see a world where people will not die early from urological cancers and diseases, and where people with problems of the bladder, kidneys, prostate and male reproductive organs can still lead full, active and productive lives.

Our mission is to improve survival and quality of life for urology patients through research, training, and education, campaigning, policy change, support and information, ensuring patients receive the best possible treatment and care and fewer lives are devastated.

## OUR AIMS

The Urology Foundation is committed to reducing the burden caused by urological diseases. We work with researchers, urology and healthcare professionals to improve the diagnosis, treatment and management of urological disease and the nation's urology care.

We rely on donations from individuals, trusts and foundations, and from companies to help fund our work. The money we raise is invested directly into research to find better treatments and cures, and in training for urology professionals to care for and help people affected by urology conditions.

The Foundation is governed by the rules and regulations set down in its company memorandum and articles of association originally dated 12 February 2009 and last updated by a special resolution on 29 June 2009.

## OUR VALUES

In undertaking our remit, we are:

- **Ambitious** to see UK urology care, treatment and practice are the best in the world.
- **Dedicated** to beating all urology diseases through research and training.
- **Proud** of working in urology and committed to transforming the lives of people with a urology condition.
- **Collaborative**; working with researchers, urologists, nurses and healthcare professionals, influencers and decision makers, charity partners, patients and their families, we are improving the nation's urology care.

## WHAT WE DO

We seek to improve patient treatment and care through investing in world class research, education and training programmes, raising public awareness and driving change in policy. We fund research that increases our understanding of urological cancers and conditions, and that can bring about change in urology practice and guidelines for the benefit of patients and their families. We are also looking for ways that can make treatments more effective and kinder. We are driving improvement

in standards in urology practice through training and we are developing the next generation of urological experts who can meet the challenge of the increased burden of disease and who put excellence of care at their core.

Awareness campaigns such as Urology Awareness Month in September bring urological cancers and conditions to the public eye, breaking the stigma and taboos associated with these diseases and conditions and encouraging people to seek an early diagnosis where they may be concerned about potential early warning signs and symptoms.

## PUBLIC BENEFIT

The Trustees have taken The Charity Commission's general guidance on public benefit into consideration in preparing their statements on public benefit contained within this annual report. In accordance with its charitable objectives, The Foundation gives grants to individuals and not-for-profit organisations to:

- Promote the study of urological cancers and conditions by supporting and carrying out research into the causes, prevention, diagnosis and method of treatment of this disease and by publishing the useful results of such research;
- Provide opportunities for training and education of health professionals working in urology, in order to advance practice and improve patient treatment and care;
- Such other purposes for the benefit of the community as shall be exclusively charitable as the Trustees from time to time shall decide.

In addition, the charity provides information on urological cancers and conditions, raises awareness, campaigns and drives policy change.

## GRANTS POLICY

The Foundation advertises its programmes and awards on its website, through its professional e-newsletter and networks. Applications for research are assessed by an independent Scientific and Education Committee (SEC) and Review Panel.

The charity is a member of the Association of Medical Research Charities (AMRC) and abides by its standards and guidelines for peer review and funding. It is also a National Institute for Health Research (NIHR) non-commercial partner. Research studies funded through our NIHR approved funding streams are automatically eligible for consideration for NIHR Research Delivery Network (RDN) support subject to meeting the standard study eligibility criteria.

## A YEAR IN VIEW

### ACHIEVEMENTS AND PERFORMANCE IN 2024

#### OUR RESEARCH STRATEGY

The Urology Foundation (TUF) was delighted to launch a new Research Strategy, ‘Improving urology health: transforming lives through research. Research Strategy 2024-2028’ in July. The Strategy was developed in consultation with a wide range of stakeholders - urology healthcare professionals and researchers, patients and their families, policy makers and wider stakeholders - to understand priorities for TUF’s work moving forward. Some clear messages came through regarding disease priority areas and types of research and programmes we should fund, and it was gratifying to see that there was significant agreement among our stakeholders on these areas. The Research Strategy is built on four key pillars, each with clearly defined objectives:

- Pillar 1 - Lead a transformation in urology health
- Pillar 2 - Understand the factors driving urological cancers and conditions
- Pillar 3 - Build and invest in our research community
- Pillar 4 - Improve outcomes for patients and their families

The strategy is a bold, exciting, and ambitious vision. Building on our achievements and informed by the knowledge and expertise of a range of stakeholders - the scientific and clinical community, nurses and allied health professionals, patients and their families, volunteers, decision makers and influencers, charity and industry partners and supporters - our aim is to significantly accelerate the progress of urological research, to advance knowledge, to invest in our scientific and medical communities and, guided by research outcomes, to drive change. At the heart of our strategy are patients and their families: involving and working with people affected by urological disease, embedding patient integration and engagement in research, and ensuring they have a “voice” in shaping future research agendas and priority areas.

#### OUR RESEARCH PROGRAMMES

##### *Innovation & Research Awards*

Our Innovation & Research Awards fund projects up to a value of £60,000 that seek to use new, exciting, innovative approaches to address urological diseases and disorders. The projects must either (a) aim to create innovative treatments or devices, (b) aim to deliver innovative care pathways or (c) aim to use innovative research techniques or methods.

We are pleased to report that eight awards totalling £499,532 were made in 2024 (in 2023 there were eight awards totalling £431,592). The eight projects were:

##### *Multi-modal cfDNA surveillance following radical treatment for high-risk penile cancer*

Penile cancer is a rare but impactful disease often diagnosed late due to limited awareness, leading to severe consequences for patients and their families. Current treatments are invasive and can leave lasting side effects, with no reliable blood tests or scans to monitor progress effectively. This project aims to revolutionise penile cancer care by developing a non-invasive blood test using “liquid biomarkers,” which are DNA fragments shed from tumours or the associated HPV virus.

The study, conducted at The Christie NHS Foundation Trust and the Cancer Research UK National Biomarker Centre, will analyse blood samples from 100 patients to detect these biomarkers. Success could mean earlier cancer detection, fewer surgeries, and better-tailored treatments, ultimately improving patient outcomes and reducing the burden on healthcare systems. This innovative

approach promises to enhance the quality of life for men with penile cancer by allowing remote monitoring and more precise treatment strategies.

*Malignant ureteric obstruction in prostate cancer: a national population-based study*

Over 50,000 men are diagnosed with prostate cancer every year across England and Wales. Half of these men have advanced cancer that spreads outside of the prostate and may cause complications to the whole body. Cancerous prostate growth may obstruct the urinary system and more specifically the tubes that drain the kidney, this is called malignant ureteric obstruction and may lead to pain, infections, kidney damage, and death. The true numbers and consequences of malignant ureteric obstruction in prostate cancer are unknown. Currently, patients and clinicians are not well-informed on who is at most risk and how best to manage this problem.

This study will use population-based data to answer key questions surrounding malignant ureteric obstruction including which patients are at the highest risk of developing the problem, the best treatments to prevent the problem and the best method of managing the problem.

*Characterising lymphatics in bladders affected by posterior urethral valves using advanced 3D imaging techniques*

Posterior Urethral Valves (PUV) are a condition that only occurs in boys and is characterised by abnormal tiny flaps of tissues at the level of the urethra, the final channel that carries urine outside the body. These tissue membranes, so called PUV, can partly block normal urine flow, which can cause problems at the level of the bladder and kidneys. In fact, around half of the boys with PUV will end up having major kidney issues requiring dialysis or transplantation. A big reason for the kidney problems is that PUV block the passage of urine, the bladder fills too much and stops functioning properly over time, which causes the kidney to become swollen and damaged.

Preserving bladder health and function is paramount to prevent kidney problems in boys with this disease. This project will determine how bladder lymphatics are laid out in health and how these change in PUV. They will conduct 3D imaging experiments utilising human bladder samples from boys undergoing surgery for PUV and will also apply this technique to a new mouse model that their lab has developed, which mimics the human disease.

*Ward Admission of Symptomatic Haematuria: an Observational multicentre sTudy (WASHOUT)*

Around 25,000 patients require emergency admission for blood in the urine each year in the UK. Patients often stay in hospital for several days, experiencing painful retention of urine, and may need blood transfusions or emergency interventions. Clinicians are not sure what the best management strategy is because there are no guidelines or evidence on how to best manage these patients. The care provided to patients in hospital may vary with the hospital they are in, the consultant on call, and other considerations such as the time of the week.

The WASHOUT study aims to observe how these patients are managed in hospital and assess important outcomes such as length of hospital stay, timing of operations, cost of scans and operations, and the frequency of re-admissions. Study findings may show which types of management have better outcomes. Findings from WASHOUT will also help clinicians to produce guideline documents and carry out clinical trials in this field.

*Gene therapy for early-onset genetic bladder disease*

This project will focus on an inherited condition that affects nerves in the bladder and can lead to kidney infections and even failure in children. The researchers have developed a gene therapy strategy to treat mice with this condition, and excitingly, were able to completely restore the function of the bladder nerves, showing the gene therapy is successful. To bring this therapy closer to the clinic the study will address two key questions:

1. What is the oldest we can effectively deliver the treatment? To inform whether the therapy is likely to be successful in babies, children, or adults.



## 2. Is therapy effective and safe in the longer term?

### *A nested case-control study of BK and JC polyomaviruses as risk factors for urothelial carcinoma in Malmö Diet and Cancer Study (MDCS) serum samples.*

The DNA of nearly all bladder cancers carry the fingerprints of damage caused by some of the cell's own proteins called 'APOBECs'. The APOBECs are enzymes which defend against infections, like BK virus, by damaging viral DNA. During BK virus infection, we have evidence that APOBECs can cause collateral damage to a cell's own DNA, potentially leading to the development of bladder cancer.

This research will look at blood samples from the Swedish Malmö Diet and Cancer Study for antibody proteins targeting BK virus. An abundance of antibodies shows that a person's immune system has recently fought BK virus. It will investigate if individuals with more BK antibodies in their blood were at increased risk of developing bladder cancer. If BK virus is shown to be a risk factor, this research could lead to many cases of bladder cancer being seen as preventable through the development of new antiviral drugs and vaccinations.

We are grateful to the Charles Reynolds Foundation for their funding towards the above six research projects.

### *Investigating combination BH3-mimetics and identifying accompanying biomarkers as a new therapeutic strategy for prostate cancer*

Prostate cancers often have increased levels of certain proteins of a family called 'BCL-2 family'. The increase in these proteins can prevent cancer therapies from successfully eliminating prostate cancer cells. A new class of drugs, called BH3-mimetics, can improve cancer cell elimination, and counteract disease recurrence by blocking BCL-2 proteins. The use of these drugs has been shown to be effective in cancers of the blood but have not been explored in depth in prostate cancer. This project will generate data on how BH3-mimetics can be used to eradicate prostate cancer cells. The ability of therapies to effectively eliminate cancer cells will be influenced by the neighbourhood in which the cancer is growing. Thus, the research aims to better understand the changes that the prostate cancer neighbourhood experiences when using BH3-mimetics and help identify which patients will benefit most from these new treatments.

### *The role of PSMA related metabolites in the progression and treatment of Prostate Cancer*

Radiotherapy is often used in conjunction with hormone therapy to treat prostate cancer. There is a set regimen which is the same for each patient. Some men may respond better or worse to radiation and the biology behind this is an active area of research. Other than PSA blood test monitoring over the longer term (months to years) there is no short term, rapid, measure of response to radiation in the prostate. Such a measure could be used to further adjust radiation for each patient, downscaling treatment to avoid side effects. This project aims to develop a convenient rapid test to monitor radiation treatment response by measuring the metabolites in the urine within existing radiation treatment appointments.

We are grateful to the John Black Charitable Foundation for their funding of the above two prostate cancer projects.

## ***Smaller Research Projects Fund***

The Smaller Research Projects Fund is focused on improving treatment and care and supports projects up to the value of £10,000. The Fund is aimed at projects that can be delivered quickly (within two years) and are focused on supporting vital research that seeks to improve the quality of clinical services and patient treatments and care.

We are pleased to report that six awards totalling £53,500 were made in 2024 (in 2023 there were five awards totalling £50,000). The projects were:

- *Understanding the impact of Out-of-Pocket Costs for Patients Receiving Stone Treatment in a Rural Region.*
- *Does invasive supervised Pelvic Floor muscle training increase membranous urethral length?*
- *Identifying the relationship between brain centre/s involved in cerebrovascular accidents and likelihood of detrusor sphincter dyssynergia in patients with suspected prostatic obstruction.*
- *Self-Targeted Relaxation Efforts for Surgical Situations (STRESS) study.*
- *Surgical outcomes for CAVAL THROMBus involved Renal Cell Cancer (IR1 - CAVALThromb): a prospective, multicentre registry.*
- *Ex vivo real-time analysis of detrusor muscle status at time of primary transurethral resection of bladder tumour (TURBT) using fluorescence confocal microscopy: IB1-LASERComplete, prospective, feasibility study.*

We are grateful to the charity Penguins Against Cancer for their co-funding of the above bladder cancer project.

### ***Our work in Urinary Tract Infections (UTIs)***

Urinary Tract Infections (UTIs) are a major health concern affecting millions globally each year. These infections not only cause pain and discomfort but all too often affect overall well-being, with many experiencing either repeated or chronic infections that significantly impact on quality of life. UTIs can also lead to more serious complications such as kidney infections, sepsis, and kidney damage if left untreated. UTIs are the second most common reason for prescribed antibiotics and have been identified by the World Health Organisation (WHO) as a significant factor in antimicrobial resistance. In 2024, The Champriss Foundation generously pledged £250,000 to be used specifically for a new research programme into UTIs.

TUF convened two Roundtable Meetings involving clinicians and researchers working in UTIs, and people with lived experience of recurrent and chronic UTIs. These meetings were to help identify:

- the challenges around UTIs and research questions that are difficult to address; and
- scope the type of research we should be funding with the donation.

The discussion on pertinent research questions and the current challenges in UTI research was focused on five areas:

- **Diagnostics:** the challenges around the poor performance of current testing methods and the fact that none of the current diagnostics listed by NICE can be recommended as effective.
- **Etiopathology** (how and why people get UTIs): this is still largely unknown with multiple factors such as genetics, hormones, diet, and use of devices such as catheters.
- **Therapeutics:** what sort of treatments might be effective, particularly thinking about reducing reliance on antibiotics.
- **Prevention:** this would feed into the above three areas as more becomes known about UTIs and their progression.
- **Types of Research and Implementation:** where research (bearing in mind the current level of research funding) might have most impact, and how to implement what is already known to be good practice.

The information from these Roundtables was used to scope the call for UTI research applications. The call was opened in September and awards are expected to be made in Spring 2025, following a robust review process with an initial Expressions of Interest round before progress to the full application round.

In addition to the above work, TUF was invited to become a partner on a James Lind Alliance, UTI Priority Setting Partnership with Antibiotic Research UK and Bladder Health UK. The TUF Director of Research sits as a charity partner member of the steering group, which includes representation from healthcare professionals working in UTIs, experts in antimicrobial infection and patients with lived experience. This piece of work will last approximately 18 months and is expected to prioritise the most important areas of research to patients and researchers.

### ***The TUF Trials Unit***

Following our successful partnership with The Centre for Healthcare Randomised Trials (CHaRT) at the University of Aberdeen to create the TUF Trials Unit (TTU), we renewed our relationship for a further three years in 2024, at funding of £60,000 per annum. During the year, the TTU managed to lever in just under £1 million of funding (£953,000) in support of the following research:

- DIETRICH: Dietary fibre supplement, inulin, given before and during radical radiotherapy to the prostate, to reduce radiotherapy side effects.
- Digital Camera-based Uroflowmetry for Early Diagnosis and Monitoring of Lower Urinary Tract Symptoms

This was in addition to the previous £6.1 million funding from the National Institute of Health and Social Care (NIHR) to conduct three large-scale, multi-centre trials across the United Kingdom:

- PARTIAL - comparing two types of surgery for kidney cancer; complete removal of the kidney or partial removal where the tumour is.
- ELIPSE - comparing surgery where the prostate and lymph glands are removed, with surgery where the prostate alone is removed.
- FOLLOW UP - a natural experiment estimating the clinical and cost-effectiveness of follow up strategies after curative treatment for prostate cancer.

CHaRT has committed to increasing capacity and proactive engagement with unit by committing more named methodologists and statisticians to support the TTU. Their work includes:

- Mentoring future urology research leaders in grant writing.
- Contributing to new methodologist and clinical research investigator collaborations.
- Providing administrative support for clinical investigators.
- Co-ordinating Patient and Public Involvement activities for specific grant requirements.
- Providing methods of support for unfunded work to underpin future grant applications.
- Delivering project support for successful funding applications before contracts are signed and funding begins.

## **TUF GRANTS MANAGEMENT SYSTEM**

During 2024 TUF implemented a bespoke grants management system, TUF Grant Tracker. The system has proven to be a comprehensive way of recording applications, recipients, reviewers, timelines, deliverable outputs, payments, sponsors, and liabilities for each grant. Through using the TUF Grant Tracker for over a year, monitoring the status of the grants has been significantly streamlined. The Tracker flags 'late outputs' which helps to ensure we receive reports from grant awardees and can therefore make timely payments. It is possible to generate records of grant awards across the four nations, regions, disease areas etc. using the system. The Tracker also provides historical data for

comparison. Both aspects have been utilised when the team needs to compile information on grants, and the Tracker enables this to be done quickly and efficiently. It has also enabled efficient collection and recall of information on research results and impact. The charity currently has over 80 active grants and awards.

## PATIENT AND PUBLIC INVOLVEMENT AND ENGAGEMENT (PPIE) PROGRAMME

In 2023 the charity launched its Patient and Public Involvement and Engagement (PPIE) programme. The PPIE Programme brings together researchers, people affected by urological cancers and conditions, their carers and the public, to help drive research forward. It is an opportunity to get involved in helping to plan, design, manage, evaluate, and communicate about research and leads to research that is relevant, appropriate, and better-designed with clearer outcomes, and is therefore well placed to have an impact. The key aims of the PPIE Programme are:

- To bring together researchers and people affected by or interested in urological cancers and conditions to drive research forward.
- To provide a source of expertise for activities within TUF.
- To ensure that the patient's voice remains central to TUF's work by providing feedback and comment on activities within the charity.

In 2024 we established the programme's workflows and developed the associated documents required to ensure a smooth process for patients and members of the public joining the programme. We also secured our place providing PPIE support for two new research projects at the Freeman Hospital and University of Nottingham. 2025 will see the charity carrying out targeted recruitment drives for these projects and meetings for patients and public to input into the projects as well as developing resources for professionals to explain the support we can offer.

In 2024 Rosie Cockroft was appointed as Grants Executive and PPIE Lead to support the growing programmes and grants portfolio and the development of our PPIE Programme. The Programme is overseen by a PPIE Development Board - members include Imran Ahmed (Professor of Urological Oncology / Urological & Robotic Surgeon at the University of Glasgow), Hannah Warren (Research Fellow, Urology Registrar), Helen Lake (Urology Nurse), Lesley Booth (specialist in public engagement within medical research) and Susannah La-Touche (Urology Consultant at St George's University Hospital).

## IMPROVING KNOWLEDGE AND SKILLS THROUGH EDUCATION AND TRAINING

### FELLOWSHIPS

Fellowships enhance urological training, education, knowledge transfer, and collaboration. They are an important stage in professional and career development, and in building and supporting outstanding surgical leaders in their field. Fellows go to study a particular specialism or technique, so they can provide that service in their own hospitals on return. Through the acquisition of new skills and knowledge, Fellows make an important contribution to the advancement of science and practice thereby ensuring better outcomes for patients. TUF offers a variety of different Fellowship opportunities.

#### *David Thompson Fellowship*

The David Thompson Fellowships are worth up to £35,000 per Fellow. The grant supports attending a centre or centres of excellence for up to one year to enable candidates to gain invaluable experience and skills in urology care and best practice, and to make contributions to research in their area of

specialty. Successful candidates will act as ambassadors promoting best practice and sharing knowledge amongst their own team, hospital, and wider urology community.

In 2024 we were again delighted to receive a number of strong applications. Thanks to the generosity of the Thompson Family Charitable Trust, which sponsors the Fellowships, we were able to make the following awards:

- Daniel McNicholas, a urology ST7 registrar at the Liverpool University Hospital Trust. He will visit the Austin Hospital in Melbourne, Australia, to gain further training in reconstruction of the urinary tract.
- Adrian Fuentes, a urology ST8 registrar at the Mater Misericordiae University Hospital, Dublin, Ireland. He will visit Princess Alexandra Hospital, Brisbane, Australia, where he will gain extensive exposure to open abdomino-pelvic oncological surgery, minimally invasive robotic techniques, and transplant surgery.
- Andy Kozan, a senior post-CCT (Certificate of Completion of Training) Teaching Fellow at Leeds University Hospitals. Andy will visit the Tenon Sorbonne University Hospital in Paris, France, where he will gain experience in robotic surgery techniques in female, functional and reconstructive urology.
- Muheilan Muheilan, a post-CST Urology Registrar at The Mater Misericordiae University Hospital, Dublin, Ireland. Muheilan will start a senior clinical fellowship in robotic pelvic surgery at the Lister hospital in Stevenage, which will expose him to a wide range of oncological cases and the possibilities of complex surgery.

We are grateful to the Thompson Family Charitable Trust for enabling these Fellowships.

#### ***Malcolm Coptcoat Travelling Fellowship***

The Malcolm Coptcoat Fellowship, worth £5,000, enables trainees to travel to international centres of excellence for a period of four to six weeks to gain invaluable experience and skills in urology care and best practice. In 2024 the Fellowship was awarded to Miss Elizabeth Day, a post-CCT Fellow based at UCL, London. Miss Day chose to visit two European Centres - the Rijnstate Hospital in Arnhem, The Netherlands, and the Martini Klinik in Hamburg, Germany. At both centres she had the opportunity to observe surgery and understand the variations in techniques to prostate and bladder cancer surgery and the rationale for these, in order to expand her understanding of the different approaches. She was also able to gain an insight into the non-technical aspects such as organisational and systems cultures, including ways of assessing continual improvement of care.

#### ***TUF/Urolink Fellowships***

The TUF/Urolink Fellowships, worth up to £1,500, are open to those senior level trainees who have completed their FRCS (Urol), enabling them to experience working in Low or Middle Income (LMIC) countries. The Fellowships help develop urological services in these countries, as well as enabling the cross-fertilisation of knowledge and skills, benefiting the professional development of both the Fellow and those working in healthcare systems where the annual per capita income is less than \$1,135 a year. In 2024 four awards were made to:

- Ravi Banthia, a Senior Clinical Urology Fellow at NHS Tayside, Dundee
- Brendon Berry, a Urology ST6 Registrar at University College Hospital, London
- Johann Boaz, a Senior Clinical Urology Fellow at Charing Cross Hospital, Imperial College
- Mike Ng, a Urology ST4 Registrar at University Hospital, Plymouth

Visits will take place in 2025 across a number of hospitals in Ghana, Malawi and Tanzania.

## SUPPORT FOR UROLOGY TRAINEES AND UROLOGY NURSES

### *Keith Yeates Medal/Ralph Shackman Prize*

The Medal and Prize are conferred when candidates achieve over 90% in their Intercollegiate Specialty Examination in Urology. In 2024 there were three winners of the medal and the Shackman travelling fellowship worth £2,000.

- Clare O'Connell, who put her prize towards her Society of Uro-Oncology Fellowship at the University of Toronto, Canada.
- Killian Daly, who visited the Department of Uro-Oncology at the University of British Columbia, Canada.
- Nicholas Simson, who attended robotic urology surgery training courses at Aalborg University in Denmark and Guy's Hospital, London.

### *Nurse Education and Training*

TUF is committed to ensuring urology nurses and allied healthcare professionals have opportunities to enhance their skills and practice and increase their specialist knowledge. We also believe career advancement goals should be supported, and that further education may open up specialist urology nursing positions in oncology or stones, or roles such as advanced nurse practitioner and urology nurse clinician. We received significant take up of TUF's Nurse Bursary awards in 2024, worth up to £5,000 each. Successful applicants were:

- Julie Lavilla, a Deputy Sister at Urology Outpatients, Nottingham University Hospitals NHS Trust, who is doing a Postgraduate Certificate at Ulster University.
- Esther Tarowera, a urology nurse at Dartford & Gravesham NHS Trust, who is doing a BSc at the University of Sunderland.
- Cyrus Solano, a Prostate Nurse Specialist at the Torbay & South Devon NHS Trust who is doing a Postgraduate Certificate at Edge Hill University.
- Claire Evans, a urology nurse at Cheshire & Wirral Community Partnership Continence & Urology Service, who is doing a Postgraduate Certificate at Edge Hill University.

In addition, we funded a further nine nurses with travel grants worth up to £500 each to attend study days and nursing conferences in the UK and Europe.

We are grateful to the Charles Reynolds Foundation for their ongoing support of these awards and opportunities for urology nurses.

### *Regional Trainee Awards and Best of the Regions*

In 2024, continuing our support for urology trainees, TUF provided £500 prizes to the Best Trainee Presentation or Paper given at a regional meeting of the British Association of Urological Surgeons (BAUS). There are 16 regions throughout the British Isles and Republic of Ireland. The winners of each region were then invited to present their papers at the annual BAUS Conference, at which the overall 'Best of the Regions' would be selected and win a further £500 prize. The overall winner in 2024 was SORCHA O'MEARA, a trainee from the Republic of Ireland, for her paper on *Holmium Yag Laser Injury in Human Ureter*.



### ***Support for Robotic Surgery Training***

Once again, TUF provided support to two of our TUF Centres of Robotic Training, to run cadaveric courses for trainees. The courses are designed for surgeons, urologists, and multi-disciplinary teams to gain system knowledge and develop a working understanding of the robot and learn technical skills useful in the operating theatre. The Freeman Hospital in Newcastle, and Guy's Hospital in London were each given £10,000 to provide the training courses over 2 days. The courses mixed lectures and videos with hands-on robotic surgery practice.

### ***Supporting Advanced Consultant Training***

TUF funded the Advanced Urology Simulation Boot Camp course with a £12,000 grant. The course is aimed at senior urology trainees and new consultants, supporting the transition to a consultant role, and provides training in often overlooked areas such as dealing with stress, effective leadership, and the day-to-day challenges of consultant practice. The course was extremely well attended and received excellent feedback.

### ***Support for Travel, Conferences and Educational Programmes***

During the year, a number of small grants were made to urologists and allied healthcare professionals to travel to, or attend, training courses, or conferences.

## **TRAINING AND EDUCATION**

As part of our commitment to training and supporting our urology community and those with an interest in urological cancers and conditions, the charity delivered training sessions and attended conferences. Highlights include:

- In May we attended the Association for Continence Professionals (ACP) annual conference in Liverpool. The ACP is a multi-professional association open to healthcare professionals working within, or who have an interest in bladder and bowel care. This was the first time TUF attended the conference, and we were delighted that TUF Chair, Mary Garthwaite, was invited to speak at the Welcome Reception. The 2024 Conference entitled "Advancing Continence Priorities" included sessions on the pharmacy role in the promotion of continence, continence research and working with the third sector.
- In June we attended the British Association of Urological Surgeons (BAUS) Annual Conference in Birmingham. TUF presence at the Conference included an exhibition stand, the TUF Session, Best of the Regions, the BSoT Run and Guest Lecture. We were delighted to welcome Patient Advocate, Alfred Samuels, who delivered the TUF Guest Lecture and who gave an insightful and moving account of his experience of prostate cancer. Alfred is an author, award winning documentary filmmaker (*A Survivor Amongst Survivors*, 2021), mentor and inspirational speaker. He has won 27 international awards, including at the London Cine Week and the Tokyo Short Film Fest.
- In November we attended the British Association of Urological Nurses (BAUN) Annual Conference in Liverpool. The conference theme was "educate, inspire, innovate, improve" and alongside hearing from keynote speakers it offered an opportunity to meet with urology colleagues and industry.

During the year TUF CEO was invited to join the Advisory Board of Knowlex. Knowlex provide a wide range of educational resources and activities for the healthcare community and commissioning organisations including conferences, panel debates, webinars, and an excellent online resource centre. The Advisory Board provides advice and insight to Knowlex and its work.

## SUPPORTING PATIENTS AND THEIR FAMILIES

### LAUNCH OF THE UTI INFORMATION SERVICE

Urinary tract infections (UTIs) are the second most common kind of infection (after chest infections). The National Institute for Health Research (NIHR 2016) report that UTIs are among the most common types of infections within excess of 92 million people affected worldwide. Around 50% of all women develop a UTI at some stage. An estimated one million women in the UK live with chronic UTIs and experience debilitating, consistent pain.

UTIs are a significant cause of mortality, especially amongst the elderly population, with UTI related symptoms accounting for between 1-3% of all primary care consultations and being the main reason for 13.7% of community antibiotic prescriptions. There is a higher-than-expected number of patients being admitted to hospital with a UTI or a UTI associated condition compared to trips, falls etc. UTIs can cause severe confusion which develops quickly over a couple of days, especially in older people.

There was a considerable body of evidence which showed people affected by UTIs would welcome information and support in understanding and managing the condition. With the generous support of The Champniss Charitable Trust and The Champniss Foundation this year saw the launch of a dedicated Nurse led UTI Information Service.

The aim of the Information Service is to provide up-to-date, quality information, support and a “listening ear” to anyone affected by or interested in UTIs including patients, their families, carers, healthcare professionals including those with an interest in UTIs, care home staff, GPs, and pharmacists. The Service responds to the needs of patients and carers for information, advice and support in understanding and managing the condition via a freephone Helpline, email and UTI Hub featuring a range of resources. The Service is open two days per week to support anyone with a concern about UTIs. This includes chronic and recurrent UTIs, symptoms and risk factors, UTIs in men, treatment options, when to request a referral to a urologist and the latest research. The dedicated email service launched on the 20 March 2024 - [nurse@theurologufoundation.org](mailto:nurse@theurologufoundation.org) and the freephone Helpline launched on the 30 July 2024 - 0808 801 1108.

The following resources were developed during the year:

- Understanding UTIs Factsheet - full guide
- UTI Essentials - for those new to UTIs
- UTIs in Older People
- Self-Care Strategies for Relief and Prevention of UTIs
- Understanding and managing recurrent UTIs
- How to talk to your GP about recurring UTIs
- Urinary Tract Infections in Men: Challenges and contemporary management - a guide for healthcare professionals

Information and training for health and social care professionals is a key part of the Service. Alongside developing dedicated resources, the Service was promoted at conferences, training sessions, and UTI clinics and via industry partners, pharmacy networks, and the media.

The Service is led by Helen Lake. A Urology Specialist Nurse with over 35 years of experience in both the NHS and the private sector, Helen is exceptionally qualified to deliver this new Service. Her expertise spans a wide range of urology conditions, including Bladder Dysfunction, Urinary Tract Infections, Bladder Pain, Prostate conditions (Prostatitis, Benign Prostatic Enlargement), Prostate



Cancer, other Urology Cancers, Erectile Dysfunction, and Male Infertility. Her career highlights include Ward Sister and a Clinical Nurse Specialist in Urology Stoma and Continence, running Nurse-Led Clinics, Lead Urology Specialist Nurse and Clinical Educator at B. Braun Medical Limited, Honorary Urology Specialist Nurse at The Newcastle upon Tyne Hospitals NHS Foundation Trust, and Specialist Urology Nurse at Convatec. Before joining the charity Helen was Director of Men's Health at Peppy Health. She is a former Trustee for the British Association of Urology Nurses (BAUN) and Nurse Advisor for The Urostomy Association. She has contributed significantly to the field through published peer-reviewed articles and as a contributing author to the RCN Guidelines on Male Infertility. Helen is affiliated with the Royal College of Nursing.

#### FEEDBACK FROM USERS OF THE UTI INFORMATION SERVICE

*'Information given and resources on the website brilliant'*

*'Thank you for being kind and welcoming'*

*'Thank you for kindly taking the time to ring me back. It was very helpful and left me feeling more positive than I have for a long time'.*

*'I am so glad to hear that there is planned research to look at future testing for UTIs that are not always picked up by current testing'*

*'Thank you so much for listening, believe me it helps. I myself have worked in the NHS for many years and it is good to see that there are people striving to help people with these conditions, and that research is ongoing'*

*Thanks for everything u have done (young enquirer)*

*Thank you so much for speaking with me, and providing a helpful summary below. After sharing the information with my GP, I have been referred to a specialist UTI clinic!*

*'I am so glad I have found you'*

#### IMPROVING PUBLIC AWARENESS OF UROLOGICAL CANCERS AND CONDITIONS

TUF is committed to improving public awareness of urological cancers and conditions, to promoting research progress and highlighting research developments, to commenting on topical issues and sharing patient experience.

#### OUR WORK IN WESTMINSTER

In February, we attended a Parliamentary Roundtable **'Driving service innovation: preparing for the future of prostate cancer care'**. The Roundtable was an opportunity to examine how current and future challenges facing prostate cancer services can be addressed through innovation in service delivery and new models of care. The event was supported by Astellas

In April we hosted a Parliamentary Reception together with the Urology Trade Association (UTA) titled: **'Putting patients first: promoting best practice in the continence sector'**. This was our third Reception with the UTA and over 80 stakeholders attended the event including policy makers, medical technology companies, researchers, clinicians, specialist nurses, funders, patients and charities. Over 14 Parliamentarians were in attendance. The reception was an opportunity to discuss continence issues and to identify what best practice in continence care should look like.

In November we attended Prostate Cancer Research's Parliamentary reception, '**Prostate Cancer Research: Cost Benefit Analysis Report**' at the House of Commons. The event saw the launch of a new report '**Socio-economic Impact of Prostate Cancer Screening**' and attracted excellent cross-party support.

In December we attended a Parliamentary drop-in event organised by Johnson & Johnson and hosted by Sadik Al-Hassan MP. TUF and Prostate Cancer Research were given the opportunity to raise key issues on cancer care with Members of Parliament. Seventeen MPs attended the event.

## CAMPAIGNS

Throughout the year we took part and supported a number of campaigns including World Cancer Day, Bladder Cancer Awareness Month, Prostate Cancer Awareness Month, "**We See You**" campaign, World Kidney Day, Testicular Cancer Month and World Continence Week. Highlights include:

- To mark Prostate Cancer Awareness Month, TUF attended an event at Network Rail's Head Office to showcase the work of the charity and to talk about prostate cancer. In March TUF staff were invited to hold an event at Kings Cross Station where they distributed free resources and held important conversations about prostate cancer with passengers.
- During Men's Health Week, UTI Information Nurse Helen Lake was interviewed by Man V Fat about men's urology health, why it's important and what they should look out for. MAN v FAT is a national movement for men who want to lose weight. They run the award-winning weight loss programme MAN v FAT Football, providing guidance, resources and community support to thousands of men every year. The video was shared with their thousands of members across the country during Men's Health Week. TUF launched a campaign web page and included information on men's health issues and health statistics.
- To mark World Continence Week 2024, we developed a new campaign '**The Face of Continence in the UK**'. We highlighted that one in five people in the UK experience bladder problems and aimed to challenge the assumption that bladder health is an older people's issue. The campaign highlighted the changing face of continence. We also produced a 'Face of Continence' video that highlighted images of people from all ages, ethnicities and demographics in a mosaic of our teardrop logo. Quotes from people and healthcare professionals were placed throughout the video to show the serious impact continence has on a person's life. We produced an infographic titled '**Spotlight on continence in the UK**' with the key stats and facts about continence alongside a series of posters. Our thanks to Convatec for their support of the campaign.

### *Urology Awareness Month*

September is Urology Awareness Month, an annual campaign which brings together our urology community - researchers, urologists, nurses and allied healthcare professionals, influencers and decision makers, patients and their families and those with an interest in urology health - to raise awareness of urological cancers and conditions.

This year's theme was '**Men's Urology Health: Myths and Legends**'. We addressed common myths around men's urology health and encouraged men to 'be a legend' and open up about their own urology health. From prostate cancer and other urology cancers to bladder issues, erectile dysfunction and kidney stones, we spent the month urging males to recognise when something's "not right below the belt" and speak out to get help. We created a range of resources to encourage good urology health including posters, infographics and informative leaflets.

As part of the campaign, we commissioned a survey via OnePoll exploring general awareness and perceptions of over 2000 men in the UK about urology health. Highlights from the survey include:

- Only four in ten men recognised the significance of a family history in the diagnosis of prostate cancer.
- Seven in ten men didn't know the function of their prostate.
- Only 53% of men could correctly identify the location of the prostate.
- Seven in ten men in the UK would delay speaking to a healthcare professional if they saw blood in their pee. One in four said they would turn to the internet for information and advice and 40% said they would drink more water. Half revealed they would only speak to a healthcare professional if it happened regularly.
- Men were more likely to think that their prostate was involved in the flow of urine (48%) than its primary function of producing fluid that becomes semen (30%).

We also ran our own survey inviting UK nurses to give their views on men's urology health and the barriers nurses face in supporting men. Highlights from the survey include:

- Over 66% of nurses believe their average male patients have 'little' or 'no' understanding of their urology health.
- Over 90% of nurses said that more than 50% of their male urology patients waited too long before seeing a healthcare professional about their symptoms.
- The most common myths nurses hear from male patients is that they think getting up several times a night to urinate is a normal part of ageing (92% of nurses agreed) followed by the myth that patients believed their chronic back pain was due to wear and tear (72% of nurses hear this from patients).
- Over 90% of nurses think common myths and misunderstandings about male urology health affect patient outcomes.
- Nurses answered that the biggest worries for men about their urology health is erectile dysfunction (88%), cancer (78%) and incontinence (72%).
- 25% of nurses said the one change that would make the biggest positive impact for their continuing education in order to benefit their patients would be to have access to more educational resources to give out to patients and the protected time to create them.

The outcomes of the surveys provided an excellent platform to secure national coverage and promote a better understanding of the issues. Our thanks to Coloplast for supporting the survey and Infographics.

Other activities during Urology Awareness Month included:

- A highly supportive video from TUF Ambassador, Sir Stephen Fry who harnessed our campaign messaging and called for men to 'Be a legend' and reach out for support.
- We attended an FA Cup Derby match between Tilbury FC and Chelmsford FC and distributed materials to supporters. Posters were displayed at Tilbury FC's stadium for the duration of the month. Tilbury FC also promoted our messages and resources via their X/Twitter account to their 7,600 followers.
- New guides including: '**Busting Myths: Men's Urology Health**' - this guide seeks to bust the myths and encourage people to recognise when to seek medical attention and '**UTIs in Men**' a guide for healthcare professionals.
- Coverage in national and international press including Mail Online and the New York Post highlighting the results of our survey.

We are grateful to everyone who supported UAM.

### *Movember*

We were delighted to support Movember's men's health campaign and their new report, '**The Real Face of Men's Health**'. The report examines how men engage with the health system and the full consequences of poor health on men, those immediately around men and those within their broader communities. It sets out recommendations that decision makers can take to improve men's health outcomes, save costs within the NHS, and tackle the health inequalities that exist between different men. The report generated incredible support and coverage - from the media to policy makers, from patients to the global Movember community.

### *National Policy Activities*

TUF has actively engaged in national policy conversations and inputted into national consultations that impact urology care throughout 2024. Highlights include:

- Working with our wider cancer community, including Cancer52 and One Cancer Voice, to collectively call on the government to commit to developing a long-term cancer strategy. We were delighted that this was successful, and the Government committed to develop a national cancer plan in 2025.
- TUF responded to the consultation on the 10 Year Plan for Health in England and will continue to call for urology to receive the policy priority it deserves.
- Working with Cancer52, TUF fed into a consultation response on the NHS Commercial Framework for New Medicines around patient access to new medicines.
- TUF joined 16 other health charities to co-sign a letter outlining our concerns about a consultation to repeal the Hospital Parking Charges Act 2022 in Northern Ireland.
- We believe that boys deserve to be educated about their own bodies and have responded to a consultation on the national curriculum urging the government to consider including education on testicular, penile and prostate health in schools across the country.

## **UROLOGY PLEDGES 2024**

In June we launched our Urology Pledges '**Excellent Urology Health for All**' to influence health policy and increase awareness of the needs of the urology field to the next generation of parliamentarians and the new government. This provided the Foundation with valuable collateral with which to engage policy makers, proposing solutions and urging prospective parliamentary candidates and then the newly elected MPs to adopt them. The pledges were:

1. Commit to investing in vital urology research
2. Commit to investing in our urology community
3. Commit to putting patients at the heart of decisions on urology care

Pre-election, we successfully launched the pledges at Cancer52's Big Conversation event in Canary Wharf, London where we discussed the pledges and key issues with advisors at the Department of Health and Social Care who were tasked with developing briefings for the incoming government on cancer policy. The document was then shared widely on social media before being discussed with the community at the BAUS Annual Conference and shared via the BAUS Weekly Newsletter. Copies of the pledges were sent to key health spokespeople in each of the main parties including the Secretary of State for Health, Wes Streeting.

## IN THE MEDIA

One in two of us will be affected by a urological cancer or condition yet these still do not attract the public profile of many other disease areas. A big part of our work is to raise the profile of urological cancers and conditions in order to encourage an early diagnosis, access to treatment and care and to ensure better outcomes and a quality of life alongside raising awareness of TUF and its vital work. Throughout the year we provided media spokespeople and commented on topical issues. Highlights included an interview on LBC on the subject of UTIs, as well as coverage in national press including The Telegraph, The Sunday Telegraph, Mail Online and The Mirror.

## LAUNCH OF THE NEW WEBSITE

Our new website launched in May and has been extremely well received. With its distinct and contemporary look, the new website reflects our breadth of activities, our wider engagement and the impact we are making. It is a platform to connect with our urology community and for those with an interest in urology including the clinical and scientific community, patients and their families, decision makers and influencers, media, charity partners, and our supporters. Alongside celebrating our achievements, offering opportunities to get involved and showcasing patient experience, the site features our UTI Information Hub and information resources for patients and their families. Sincere thanks to The Champniss Foundation and The Champniss Charitable Trust for their generous support of the new website.

## COLLABORATIONS AND PARTNERSHIPS

We value the importance of working with other organisations to achieve our aims. Throughout the year we engaged with a range of organisations and charity partners working in the area of urology. These included the BAUS, BAUN, Urology Trade Association, Prostate Cancer UK, Prostate Cancer Research, Fight Bladder Cancer, Action Bladder Cancer, Kidney Cancer UK and UCare.

TUF CEO was appointed as Vice Chair of Cancer52. Cancer52 is an organisation that represents over 100 charities and patient organisations focused on rare and less common cancers.

We were delighted to become a member of One Cancer Voice. One Cancer Voice is a coalition of over 60 cancer charities that advocate for better cancer care and outcomes in England and is coordinated by Cancer Research UK.

We welcomed the opportunity to meet and work with a range of companies including Medac Pharma, Johnson & Johnson, Androlab, Peppy Health, Intuitive Health, Boston Scientific, Pfizer UK, Peak Medical Ltd, Astellas Pharma, Bayer, Lloyds Pharmacy Online Doctor, Coloplast and Convatec to promote awareness of urology health.

## CREATING STRONG FOUNDATIONS: INVESTING IN OUR TEAM

Developing our people and infrastructure is vital as it underpins the delivery of our charitable activities. The Trustees committed to infrastructure investment to support sustainability, effectiveness, collaboration and impact, particularly within the charity's programmes and grants portfolio which has expanded significantly over the last three years, across fundraising and the expansion of funding streams and to ensure we have a "voice" within the urology community - in driving change, improving outcomes and patient care. The first stage of the investment saw the appointment of Laura Thorne as the new Director of Communications and Policy in 2023.

The second stage of the investment saw the following appointments in 2024:

- Claire O’Sullivan, Fundraising Manager (Events and Individual Giving), to manage and expand a portfolio of events, to develop an individual giving programme and to grow the supporter base.
- Rosie Cockroft, Grants Executive and PPIE Lead, to support for the growing programmes and grants portfolio and the development of our PPIE Programme.
- The appointment of dedicated support for the Major Appeal to support the delivery of the new Research Strategy.

## PLANS FOR THE FUTURE


In 2025 we will continue to build on our work and achievements alongside:

- Delivering our Research Strategy ‘**Improving urology health: transforming lives through research. Research Strategy 2024-2028**’ and campaigning for further investment in research. The launch of our Research Appeal will aim is to raise £5million to support the delivery of the new Strategy.
- Investing in and supporting our urology community, the next generation of urology researchers and allied healthcare professionals through the expansion of our research, training and education programme, study and travel awards and other opportunities.
- Developing our work in UTIs and bladder health through the UTI Research Programme, expanding the Nurse-led UTI Information Service, training and education resources, developing our work as a partner on the James Lind Alliance (JLA) Chronic and Recurrent Urinary Tract Infection Priority Setting Partnership (PSP), campaigning and awareness raising.
- Delivering on our Communications Strategy to
  - Raise awareness of urology health and the work of The Urology Foundation.
  - Drive change in urology care and practice through our policy work, campaigning and health awareness initiatives.
  - Improve patient outcomes by delivering change in specific urology areas based on research outcomes and patient need.
  - Strengthen our partnerships with the wider urology community to drive meaningful change.
- Giving a voice to the people affected by or at risk of urological disease ensuring they have the opportunity to be heard, to influence and drive change. We will look to support and develop closer relationships with seldom heard communities, those at greater risk of specific disease and those with poorer outcomes.
- Raising awareness and developing our campaigning and policy work in urological cancers and conditions with a particular focus on prostate cancer, UTIs and bladder health including urinary incontinence and bladder cancer.
- Mark the 30<sup>th</sup> Anniversary of TUF: highlight the charity’s history and impact, celebrate our achievements and commitment to changing the future / face of urology.



## FINANCIAL REVIEW

### FINANCIAL RESULTS OF ACTIVITIES & EVENTS



The total value of net assets held by The Urology Foundation on 31 December 2024 was £3,762,840 (2023 £3,111,987). The Foundation's fundraising activities and other initiatives during the course of 2024 generated a total of £2,018,269 of voluntary income (2023 £1,384,437) and a further £50,874 (2023 £66,800) from specific fundraising event income.

### FUNDRAISING

The Foundation is reliant on voluntary income to fulfil its remit. Following a review of the charity's fundraising function in 2022, the decision was made to invest in this area in order to diversify the existing income streams and to look to increase the charity's income. Our new fundraising initiatives have contributed to this growth, particularly Trusts and Foundations and the business community providing the charity with diversified, sustainable sources of income. We are pleased to report income for year totalled £2,090,290 against the previous year total of £1,470,272. The following information summarises the various disciplines:

- **Donations.** Income from donations totalled £186,971.
- **Legacy.** During the year The Foundation was fortunate to receive a generous legacy of £697,285. This gift will support scholarships - advancing knowledge, skills and careers or our urology community.
- **Business Community Engagement.** We are proud to collaborate with a wide range of companies, including those in the pharmaceutical and MedTech sectors to help achieve our mission. Under the leadership of our Business Development Manager, we have significantly expanded our corporate engagement while continuing to strengthen long-standing partnerships. Highlights from the year include a Parliamentary Reception in collaboration with the Urology Trade Association (UTA) to bring key stakeholders together to discuss pressing issues in urology and community events at ASDA, helping to engage the public and raise awareness of urology issues. We partnered with Network Rail' Wellbeing Champion to promote awareness across the business. For World Continence Week we collaborated with Convatec to break down the stigma surrounding continence issues, promoting openness about

its impact on quality of life. Coloplast continued their support for UAM initiatives. Medac Pharma and Johnson & Johnson provided generous grants to fund two new bladder cancer projects which we will be delivering in 2025. Boston Scientific kindly supported the annual Bike4TUF. Looking ahead to 2025, we aim to further develop existing relationships while also exploring new partnerships to expand our reach and deliver even more impactful projects. We are deeply grateful to our many corporate partners for their continued support and generosity. Their contribution plays a vital role in enabling our work to improve the lives of those affected by urological cancers and conditions.

- **Trusts and Foundations.** Income from a range of both small and large trusts and foundations totalled £951,002 and included support towards research, awareness, community-based projects, education and training. This included a grant from The UK Government Post COVID Recovery Medical Research Charity Support Fund totalling £351,264 towards helping to sustain early-career researchers supported by medical research charities impacted by the COVID 29 pandemic.
- **Events.** We are delighted that so many of our supporters and friends organised and took part in a wide range of events throughout the year. These included the TUF Sri Lanka Trek which saw our President Professor Roger Kirby and former Trustee Roland Morley together with TUF supporters raised an incredible £101,180. His Excellency, Rohitha Bogollagama, Sri Lanka High Commissioner kindly hosted a Reception on the 11 November which was attended by many of the cyclists and TUF staff. The ever-popular London Landmarks Half Marathon (LLHM) saw seven runners take to the streets of London to raise over £5,400. Bike4TUF London to Nantes, 13-16 June 2024 was led by Consultant Urologist, Ben Starmer, Ben Challacombe and TUF supporter David Plummer and saw 28 supporters cycle over 300 miles and raise £40,000. This is one of the highest amounts raised from this popular annual event. BSoT TUF Fun Run returned to the 2024 BAUS Conference, with an impressive 50 runners completing an early morning 5km run - over £1100 was raised. Three supporters took part in the popular Vitality 10,000 London 10K run raising over £110. The Royal Parks Half Marathon was a new addition to the Challenge Events programme and our runners raised an impressive £1,330. During the month of June, we launched a new fundraising awareness campaign - Bake4TUF - in which we encouraged supporters to host a bake sale and encourage people to talk about urology health. We are grateful to all our supporters and friends for their incredible efforts and fundraising challenges including Simon Lord who undertook 24 hours cycling challenge from London to Amsterdam and Bill Hall and friends who completed the West Highland Way Walk.

We are registered with the Fundraising Regulator and adhere to the code of fundraising when carrying out our activities. Our staff are committed to following codes of good practice and standards developed by the fundraising community through the work of the Chartered Institute of Fundraising (IoF) and other professional bodies. The Foundation operates a clear and stringent complaints handling procedure that is reported to the Senior Management team and the Board. As part of our supporter care programme, we have agreed policies and procedures in place and written agreements with external agencies that we engage to help us or who raise funds for the charity. We ensure that anyone engaged to work for us is trained in and respects our aims and objectives and carries out their activities with the same high standards and care we would ourselves. During the year we received less than five complaints in relation to our fundraising activities. We remain committed to improving our practice, learning from supporter feedback.

## RESERVES & LIQUIDITY POLICY

The Foundation currently total funds of £3,762,840 of which £1,813,138 are held as restricted funds, £2,921 are held as tangible fixed assets and £1,550,000 are held as designated funds (£500,000 minimum required reserves, £800,000 for research and £250,000 for infrastructure - see details below). Therefore, the Foundation has 'free reserves' of £396,781 (31 December 2023: £2,213,621).



The Foundation's policy is to maintain reserves sufficient to continue to fund its objectives on a long term basis, and to ensure that the charity operates with an adequate level of liquidity to (i) minimise the risk associated with a temporary or unforeseen shortfall in liquidity; (ii) manage its cash and investments to meet its liabilities and remain a going concern for at least 1 year in the event of an unplanned drop in income. Liquidity is defined as cash and the investment portfolio held as unrestricted funds. The Policy establishes a minimum liquidity target of £500,000 ("Minimum Required Reserve") subject to future modification by the Finance Committee and Trustees' approval.

The Trustees consider that reserves held in excess of the amounts required to fund all future commitments together with the initial fund of £500,000, will be available to increase its visibility and expand its operations including funding for further research and a wider range of projects. The Trustees plan levels of expenditure from unrestricted and restricted funds for the year ahead based upon the level of incoming resources for the current year as well as utilising restricted funds.

## DESIGNATED FUNDS

In September 2024 the Board of Trustees approved designated funds for the following purpose:

Research Strategy 2024-2028 and Research Appeal	A dedicated fund to support the new Research Strategy 2024-2028 and associated Research Appeal. The strategy is an exciting and ambitious plan to improve urology health and transform lives through research over the next five years. It builds on our history of clinical and academic innovation that has already helped to revolutionise urology care. Trustees have agreed to designate £1.5 million to enable the charity to achieve its long-term vision and mission. £800,000 of this is funded from designated unrestricted funds and £700,000 from a restricted legacy donation for scholarships.
Infrastructure	A dedicated fund of £250k to invest in the development of the charity's infrastructure including patient experience, campaigning, marketing, communications and to advance our fundraising capabilities to further diversify income and secure long-term sustainability.

## STATEMENT OF GOING CONCERN

The Foundation's unrestricted net funds generated in 2024 are judged to be sufficient to meet the requirements of the charity for charitable giving in the coming year.

## INVESTMENTS POLICY

The Foundation's investments are managed by Rothschild Bank (CI) Limited. The Treasurer and the Chief Executive are responsible for managing the relationship with Rothschild but changes in investment strategy are subject to approval by the Board of Trustees. The investment manager is asked to attend at least one Board of Trustees and one Finance Committee meeting annually.

The Board follows a medium risk 'Balanced' investment strategy which is intended to achieve steady growth over the long term through a diversified approach to investment. Capital preservation in real terms over a long-term horizon is the primary objective and some volatility is acceptable in order to achieve this. The charity's investments are held in the Exbury Fund, an ethical portfolio managed by Rothschild. The fund achieved a 7.2% return over 2024.

All other Foundation funds are held in accounts with the charity's bankers, National Westminster Bank plc.

## REMUNERATION POLICY

In setting salary levels, The Urology Foundation follows the National Council for Voluntary Organisation's guidance that a charity's pay policy should be to offer fair pay to attract and keep appropriately-qualified staff to lead, manage, support and/or deliver the charity's aims. It also conducts online research of charity salaries and uses surveys to benchmark levels of pay. The Urology Foundation does not automatically award its staff with annual salary increases, either incremental or cost of living.

## PENSIONS POLICY

The charity offers a stakeholder pension, operated by The People's Pension (B&CE Holdings), in line with statutory requirements. All new staff are automatically enrolled but can opt out if desired.

## EQUAL OPPORTUNITIES AND DIVERSITY POLICY

The charity is committed to being an Equal Opportunities employer and to respecting diversity, and is determined to ensure that no job applicant, employee, or Trustee receives less favourable treatment on the grounds of their age, disability, gender reassignment, marriage and civil partnership, pregnancy or maternity, race, religion or belief, sex or sexual orientation. The charity also seeks to ensure that its employees are not victimised or subjected to harassment.

The policy applies to recruitment and selection for jobs in the Foundation, career development and training, promotion, performance management, pay, redundancy, disciplinary and grievance procedures, the application of terms and conditions of employment and any other aspects of employment with the Foundation.

The policy also applies to third parties such as Trustees and committee volunteers, clients (i.e. grant applicants) and suppliers.

## PRINCIPAL RISKS AND UNCERTAINTIES

The Trustees take the management of risks seriously. The Chair of the Board of Trustees and the Chief Executive are charged with responsibility to ensure that the risks which have been identified are adequately assessed and properly mitigated on a regular basis. The potential risks have been discussed with the Chairman and the charity and a formal risk register is kept, updated and discussed by the Finance Committee and Board of Trustees on a quarterly basis.

### *Impact of war in Ukraine and economic outlook*

The ongoing war in Ukraine and wider economic outlook have broader economic implications, some of which will be reflected in our investment fund holdings. Our Investment Manager keeps us regularly updated and there is no immediate cause for concern or action.

### *Risks to Data*

The charity takes its responsibilities for data very seriously. We follow a Data Protection policy based on the GDPR and have a nominated Trustee (Mr Mark Becker) who has Board oversight for data compliance. We use a professional data base provider that stores all information in the cloud and this is secured using a two-step password verification. We review our records on an ongoing basis and

delete old or historical records that are no longer relevant, and remove people who no longer wish to hear from us (provided that there is no financial information that we need to retain).

Other key risks are assessed as follows:

Governance /Environmental	Impact of the external environment on fundraising, in particular: public confidence in charities; new fundraising regulations; Data Protection Regulations.
Income Sources	TUF is reliant upon voluntary income as an annual source of funding. It is the role of the Trustees to manage risk exposure on fundraising activities and in doing so to accept an appropriate level of risk in order to raise income from a wide range of sources.
Risk of data breach	The charity uses a professional database provider that stores all information in the Cloud and this is secured using a two-step password verification. The charity's own day to day working documents are also stored on a cloud-based system. TUF staff are regularly made aware of possible phishing scams and to be alert to any potential email or system data breaches.
Key Person risk	The small staff base makes TUF heavily reliant on the Chief Executive and a few key Trustees so the unexpected loss or departure of the Chief Executive or certain Trustees is a risk. Succession planning processes are in place.
Investment Risk	TUF's success is directly related to the amount of resource it can devote to its objectives, so the key risk identified by Trustees relates to the proper management of its funds. Imprudent or unprofessional decisions could majorly impact on the performance of those funds. In common with similar charities, TUF employs professional fund managers, whose performance is regularly reviewed by the Treasurer together with other Trustees.
Risk to Employees	Employees are not subject to risks other than those likely to be associated with routine office work. Apart from obtaining statutory Employers Liability Insurance, TUF nonetheless treats the welfare of its staff as a priority. The Chief Executive is the Nominated Safety Officer for the purposes of the Health and Safety at Work Act. The premises are checked and maintained by the landlord / managing agency to ensure appropriate mitigation of the risk of fire. Employees are aware of the location of fire extinguishers. The charity also has a number of policies in place covering Equal Opportunities, Lone Working, Working from Home and Safe Guarding Vulnerable People.
Risk that research fails to deliver results	Grants awarded are subject to rigorous review by the SEC and Reviewing Committee. Grantees are expected to submit progress reports and these are reviewed by the SEC and TUF. The charity maintains ongoing communication with grant holders.
Loss of Records	To protect against the loss of records, and to increase data security, files are stored in the cloud. The risk of any unsaved data being critical to TUF is regarded as insignificant. Other similar risks are dealt with by insurance.

## STRUCTURE, GOVERNANCE & MANAGEMENT

The Urology Foundation is a charity and a company limited by guarantee and was established on 12 February 2009 to incorporate the charitable activities of the British Urological Foundation (BUF), an unincorporated charitable trust established in 1994 by the British Association of Urological Surgeons and BJU International, and a registered charity since 17 March 1995. The Urology Foundation itself became a registered charity on 19 March 2009.

### CHARITY GOVERNANCE CODE

The Board and Executive of the charity abide by the standards set by the Charity Governance Code when executing their duties. The overall strategic direction of the charity is determined by the Trustees, who meet three times each year including an Annual General Meeting.

### TRUSTEE RECRUITMENT, TRAINING AND INDUCTION

The Foundation seeks to achieve a balance of lay and medical Trustees. Appointed Trustees are recruited on the basis of fulfilling the criteria to provide a balance of experience and knowledge. Members of the charity's Scientific and Education Committee (see below) are recruited through calls in industry publications.

All new Trustees are provided with an induction programme and an induction pack. They are provided with relevant Charity Commission publications and regularly briefed on developments and opportunities that will support their general understanding of the voluntary sector, healthcare and medical research issues.

Trustees contribute to every aspect of the charity: governance; fundraising; financial planning; management expertise and leadership. We are truly grateful for their service and to all our Trustees, who selflessly contribute their time, expertise and networks whenever they are called upon.

### APPOINTMENT & ELECTION

The Trustees and Chairman are appointed for an initial period of three years that can be extended for a further three-year term. A further extension may be made if it is deemed to be in the best interests of the Charity. The governing document requires that there should be a minimum of seven Trustees.

Two of the Trustees are required to be representative Trustees, one nominated by The British Association of Urological Surgeons (BAUS) and one nominated by British Journal of Urology International (BJUI). All other Trustees, known as appointed Trustees, are appointed by unanimous written resolution of all the Trustees present and/or voting at a special meeting of Trustees called to take place immediately before or after an ordinary meeting of Trustees.

The representative Trustee nominated by BAUS is the President of BAUS and the appointment to the board is concurrent with their post at BAUS, which is for a period of two years.

#### ***The Executive Team***

The Chief Executive is responsible for the day-to-day management of the charity.

The Chief Executive deals with the implementation of policy and strategic decisions taken by the Board of Trustees. She and the appropriate staff members attend the meetings of the Board of Trustees and sub-committees, and report on the day-to-day operations of the charity. The Foundation currently operates the following sub-committees:

### ***Scientific and Education Committee (SEC)***

The SEC is responsible for the development and assessment of The Foundation's research, education and training programmes and the review and administration of The Foundation's grant making policy. The Chairman of the SEC is also a member of the Board of Trustees, and reports back to the Board on the work of the Committee. The SEC is made up of clinical and academic urologists and scientists with an interest in urology, and lay representatives.

### ***Research Review Panel***

The Research Review Panel is responsible for assessing applications for our major research grants and marking these according to the requisite criteria being met. In this task it assists the SEC in its final decision on who should receive grants. The Research Review Panel is made up of clinical Trustees and academic urologists and scientists with an interest in urology.

Membership of the SEC and Review Panel can be viewed on the charity's website. They provide their services as volunteers and we are enormously grateful to them.

### ***Finance Committee***

The charity Finance Committee is chaired by the Treasurer, Ms Angela Daniel. Membership includes The Chair of the Board and the Chairman of the SEC, and two other Trustees and the Chief Executive. Any recommendations made by the Finance Committee are brought to the Board of Trustees for discussion and ratification. The Treasurer has oversight of the charity's bank and investment accounts.

### ***IT Oversight Committee***

The IT Oversight Committee was formed in 2023 on the recommendation of the Board of Trustees. The purpose of the IT Oversight Committee is to advise the Board of Trustees on IT governance, IT implementation and other strategic IT-related issues including legal and regulatory compliance, investment in IT projects including telecommunications, risk and opportunities and to ensure these are managed through appropriate internal controls. The IT Oversight Committee consists of a minimum of three Trustees including the Chair, the Chief Executive, Director of Research and Senior Administrative Officer.

## **RELATIONSHIPS WITH RELATED PARTIES**

The Urology Foundation continues to maintain close links with its two founding charities, BAUS and the BJUI, whose representatives are Trustees.

## **REPRESENTATION ON OTHER BODIES**

The Urology Foundation is a member of the Association of Medical Research Charities (AMRC), which confers a quality mark for our peer review processes, as well as advocating for charity-funded research with government. The charity is a National Institute for Health Research (NIHR) non-commercial Partner. This means the studies that the Foundation funds may be eligible to access the NIHR Study Support Service which is provided by the NIHR Clinical Research Network.

The charity is also a member of Cancer52, Charities Research Involvement Group, the National Council for Voluntary Organisations (NCVO), Charity Finance Group, One Cancer Voice and UNSEEN, a UK leading anti-slavery charity working with survivors, businesses, governments, police and NHS to end slavery.

## REFERENCE AND ADMINISTRATIVE DETAILS

The registered charity name is “The Urology Foundation” (sometimes referred to as “TUF”), a charity and a company limited by guarantee.

### Trustees

Ms Mary Garthwaite (Chair)  
Ms Angela Daniel (Treasurer)  
Mr Mark Becker (Secretary)  
Prof Rakesh Heer  
Ms Hilary Baker (appt 21 March 2024)  
Mr Mo Belal (appt 21 March 2024)  
Mr Ben Challacombe  
Ms Jo Creswell (resigned 17 June 2024)  
Mr Mike Griggs  
Prof Alan McNeill  
Mr Roland Morley (resigned 21 March 2024)  
Mr Kieran O’Flynn  
Mr Ian Pearce (appt 17 July 2024)  
Ms Julia Taylor (appt 21 March 2024)  
Ms Hannah Warren

### President

Prof Roger Kirby

### Patrons

Mr Handel Evans  
Sir Ranulph Fiennes OBE  
Mrs Rosemary Macaire  
Ms Jane Macquitty MBE  
Mr Steven Norris

### Ambassadors

Mr Alex Corbisiero  
Sir Stephen Fry  
Mrs Kate Holmes

### Chief Executive

Ms Rebecca Porta

### Registered Office

1-2 St Andrew’s Hill  
London  
EC4V 5BY

### Charity number

1128683 (England & Wales)

### Company number

06817868

### Auditors

Sumer Auditco Limited  
Hermes House,  
Fire Fly Avenue,  
Swindon, Wiltshire, SN2 2GA

### Bankers

National Westminster Bank plc  
PO Box 2021  
10 Marylebone High Street  
London W1A 1FH

### Investment Manager

Rothschild Bank (CI) Limited  
St. Julian’s Court, St. Julian’s Avenue  
St. Peter Port  
Guernsey GY1 3UA

## TRUSTEES' & DIRECTORS' RESPONSIBILITIES IN THE PREPARATION OF FINANCIAL STATEMENTS

The Trustees (who are also the directors of The Urology Foundation for the purposes of company law) are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company as at the balance sheet date, and of the incoming resources and application of resources, including income and expenditure, for that period. In preparing those financial statements, the Trustees and directors are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The Trustees are responsible for keeping proper accounting records, which disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with Companies Acts 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from the legislation in other jurisdictions.

### AUDITOR

Following a review of auditors, the charity's Trustees appointed Sumer Auditco Limited to undertake the 2024 audit. Mr James Gare (FCA), of Sumer Auditco Limited has agreed to act as Auditor.

### STATEMENT AS TO DISCLOSURE OF INFORMATION TO THE AUDITOR

The Trustees and directors at the date of approval of this Trustees' annual report confirm that so far as each of them is aware, there is no relevant information of which the charity's auditor is unaware, and the Trustees and directors have taken all steps that they ought to have taken to make themselves aware of any relevant information and to establish that the auditor is aware of that information.

A handwritten signature in black ink, reading "M. Garthwaite".

Mary Garthwaite, Chair

Date: 21/09/2025



Report of the Independent Auditors to the Members of  
The Urology Foundation (Registered Number:06817868)

### **Opinion**

We have audited the financial statements of The Urology Foundation (the 'charitable company') for the year ended 31 December 2024 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2024 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### **Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

### **Other information**

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.



Report of the Independent Auditors to the Members of  
The Urology Foundation (Registered Number:06817868)

**Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Report of the Trustees for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Report of the Trustees has been prepared in accordance with applicable legal requirements.

**Matters on which we are required to report by exception**

In the light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Report of the Trustees. We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to take advantage of the small companies exemption from the requirement to prepare a Strategic Report or in preparing the Report of the Trustees.

**Responsibilities of trustees**

As explained more fully in the Statement of Trustees' Responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

**Our responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Based on our understanding of the charity and its grant making activity, we identified that the principal risks of non-compliance with laws and regulations related to health and safety, employment law, Companies Act 2006 and Charity Law, and we considered the extent to which non-compliance might have a material effect on the financial statements of the charity. We also considered those laws and regulations that have a direct impact on the preparation of the financial statements such as the Companies Act 2006 and the Charities Statement of Recommended Practice.

We evaluated management's incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls) and determined that the principal risks were

Report of the Independent Auditors to the Members of  
The Urology Foundation (Registered Number:06817868)

related to revenue recognition, management override, occurrence of grants and completeness of grants payable, and the potential lack of segregation of duties. Audit procedures performed by the audit engagement team included:

- discussions with management, including consideration of known or suspected instances of non-compliance with laws and regulations and fraud;
- understanding and review of management's internal controls designed to prevent and detect irregularities, and fraud;
- review of the minutes of the Trustees meetings;
- review of tax compliance;
- designing audit procedures to incorporate unpredictability;
- performing analytical procedures to identify any unusual or unexpected relationships that might indicate risks of material misstatement due to fraud;
- review of the financial statements disclosures and testing to supporting documentation to assess compliance with relevant laws and regulations discussed above;
- enquiring of management about actual and potential litigation and claims;
- testing transactions entered into outside of the normal course of the charity's business; and
- identifying and testing journal entries, in particular any journal entries with fraud characteristics such as journals with round numbers.

There are inherent limitations in the audit procedures described above and the further removed non-compliance with laws and regulations is from the events and the transactions reflected in the financial statements, the less likely we would become aware of it. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our Report of the Independent Auditors.

**Use of our report**

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.



James Gare FCA DChA (Senior Statutory Auditor)  
for and on behalf of Sumer Auditco Limited  
Statutory Auditors  
Hermes House  
Fire Fly Avenue  
Swindon  
Wiltshire  
SN2 2GA

22/09/2025  
Date: .....

STATEMENT OF FINANCIAL ACTIVITIES  
for the year ended 31 December 2024

	Note	Unrestricted Funds £	Restricted Funds £	Total 2024 £	Total 2023 £
<b>INCOME</b>					
Donations and legacies	1	316,232	1,702,037	2,018,269	1,384,437
Other trading activities	2	50,874	-	50,874	66,800
Investments	3	21,147	-	21,147	19,035
<b>TOTAL INCOME</b>		<b>388,253</b>	<b>1,702,037</b>	<b>2,090,290</b>	<b>1,470,272</b>
<b>EXPENDITURE</b>					
<b>Raising Funds</b>					
Donations and legacies	4	41,843	2,039	43,882	35,852
Trading activities	5	46,201	2,009	48,210	37,315
Investment management costs		-	-	-	78
<b>Expenditure on Charitable activities</b>					
Raising Awareness	6	167,654	8,038	175,692	137,135
Grant making	7	548,218	789,958	1,338,176	1,078,079
<b>TOTAL EXPENDITURE</b>		<b>803,916</b>	<b>802,044</b>	<b>1,605,960</b>	<b>1,288,459</b>
Net Gains on investment assets	11	166,315	208	166,523	(289,833)
<b>NET (EXPENDITURE)/INCOME</b>		<b>(249,348)</b>	<b>900,201</b>	<b>650,853</b>	<b>471,646</b>
Transfer between funds		(14,571)	14,571	-	-
<b>NET MOVEMENT BETWEEN FUNDS</b>		<b>(263,919)</b>	<b>914,772</b>	<b>650,853</b>	<b>471,646</b>
<b>RECONCILIATION OF FUNDS</b>					
Fund balances brought forward at 1 January 2024		2,213,621	898,366	3,111,987	2,640,341
<b>FUND BALANCES CARRIED FORWARD AT 31 DECEMBER 2024</b>		<b>1,949,702</b>	<b>1,813,138</b>	<b>3,762,840</b>	<b>3,111,987</b>

The net movement in funds for the year arises from the charity's continuing operations.

No separate statement of total changes in equity has been presented as all such gains and losses have been dealt with in the statement of financial activities.

*The notes on pages 39 to 50 form part of these accounts*

**THE UROLOGY FOUNDATION**  
**STATEMENT OF FINANCIAL ACTIVITIES**  
**for the year ended 31 December 2023 (Full fund comparative)**

	Note	Unrestricted Funds £	Restricted Funds £	Total 2023 £
<b>INCOME</b>				
Donations and legacies	1	140,195	1,244,242	1,384,437
Other trading activities	2	66,800	-	66,800
Investments	3	19,035	-	19,035
<b>TOTAL INCOME</b>		<b>226,030</b>	<b>1,244,242</b>	<b>1,470,272</b>
<b>EXPENDITURE</b>				
<b>Raising Funds</b>				
Donations and legacies	4	24,761	11,091	35,852
Trading activities	5	21,357	15,959	37,315
Investment management costs		78	-	78
<b>Expenditure on Charitable activities</b>				
Raising Awareness	6	82,382	54,753	137,135
Grant making	7	198,193	879,886	1,078,079
<b>TOTAL EXPENDITURE</b>		<b>326,771</b>	<b>961,689</b>	<b>1,288,459</b>
Net Gains on investment assets	11	289,471	362	289,833
<b>NET INCOME</b>		<b>188,730</b>	<b>282,915</b>	<b>471,646</b>
Transfer between funds		(59,706)	59,706	-
<b>NET MOVEMENT BETWEEN FUNDS</b>		<b>129,024</b>	<b>342,621</b>	<b>471,646</b>
<b>RECONCILIATION OF FUNDS</b>				
Fund balances brought forward at 1 January 2023		2,084,597	555,744	2,640,341
<b>FUND BALANCES CARRIED FORWARD AT 31 DECEMBER 2023</b>		<b>2,213,621</b>	<b>898,366</b>	<b>3,111,987</b>

The net movement in funds for the year arises from the charity's continuing operations.

No separate statement of total changes in equity has been presented as all such gains and losses have been dealt with in the statement of financial activities.

*The notes on pages 39 to 50 form part of these accounts*

**THE UROLOGY FOUNDATION**

**BALANCE SHEET**  
**as at 31 December 2024**


Company Number 06817868

	Note	2024 £	2023 £
<b>FIXED ASSETS</b>			
Tangible assets	10	2,921	3,895
Investments	11	3,637,562	3,453,644
		<u>3,640,483</u>	<u>3,457,540</u>
<b>CURRENT ASSETS</b>			
Debtors	12	1,226,409	440,181
Cash at bank and in hand		214,796	415,083
		<u>1,441,205</u>	<u>855,264</u>
<b>LIABILITIES: amounts falling due within one year</b>	13	792,092	966,337
<b>NET CURRENT ASSETS/(LIABILITIES)</b>		<u>649,113</u>	<u>(111,073)</u>
<b>LIABILITIES: amounts falling due in more than one year</b>	13	526,756	234,479
<b>NET ASSETS</b>		<u>3,762,840</u>	<u>3,111,987</u>
<b>THE FUNDS OF THE CHARITY</b>			
<b>Restricted income funds</b>	15		
Robotic Surgery Training Fund		83,964	106,448
Prostate Cancer Research Fund		197,616	208,149
Champriss Fund		416,595	344,862
Team Corbs - Testicular		7,314	7,313
Charles Reynolds		9,461	13,002
Thompson Family Charitable Trust		212,086	126,556
Innovation & Research Awards		137,475	85,197
Small Research Projects		44,502	-
Events		6,840	6,839
Vivienne Irene Meader - Scholarships		697,285	-
<b>Total Restricted income funds</b>		<u>1,813,138</u>	<u>898,366</u>
<b>Unrestricted income funds</b>	15		
General Fund		399,702	1,713,621
Designated Fund (British Urology Foundation)		500,000	500,000
Research Strategy 2024-2028 and Research Appeal		800,000	-
Infrastructure		250,000	-
<b>TOTAL CHARITY FUNDS</b>	16	<u>3,762,840</u>	<u>3,111,987</u>

These financial statements have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small charitable companies and with the Financial Reporting Standard 102.

The financial statements on pages 35 to 38 were approved by the trustees and authorised for issue on 19 September 2025, and are signed on their behalf by

*M. Garthwaite*  
..... Chair  
**Mary Garthwaite**  
21/09/2025

  
Angela Daniel (Sep 22, 2025 11:54:22 GMT+1)  
..... Treasurer  
**Angela Daniel**  
22/09/2025

*The notes on pages 39 to 50 form part of these accounts*

THE UROLOGY FOUNDATION

STATEMENT OF CASHFLOWS  
for the year ended 31 December 2024

	Note	2024 £	2023 £
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>	14		
Net cash used in operating activities		(200,286)	(162,921)
<b>Cash flows from investing activities:</b>			
Dividends and interest from investments		17,394	14,039
Management fees paid from investments		-	(78)
Purchase of equipment		-	(1,856)
Transfer from cash		-	-
Proceeds from sale of investments		319,643	551,126
Purchase of investments		(337,038)	(307,833)
<b>Net cash used in investing activities:</b>		(1)	255,399
Change in cash and cash equivalents in the reporting period		(200,287)	92,477
Cash equivalents at the beginning of the reporting period		415,083	322,605
Cash and cash equivalents at the end of the reporting period		214,796	415,083

*The notes on pages 39 to 50 form part of these accounts*



## THE UROLOGY FOUNDATION

Financial statements for the year ended 31 December 2024

### ACCOUNTING POLICIES

---

#### STATUTORY INFORMATION

The Urology foundation is a company limited by guarantee, without share capital, registered in England and Wales. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity. The charity's registration number is 1128683, registered company number is 06817868 and registered office address is 1-2 St Andrew's Hill, London EC4V 5BY.

#### BASIS OF ACCOUNTING

The financial statements have been prepared under the historical cost convention with items recognised at cost or transaction value unless otherwise stated in the relevant notes to these accounts. The financial statements have been prepared in accordance with the Statement of Recommended Practice: Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 1 January 2019 and Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102) and Charities Act 2011. The trust constitutes a public benefit entity as defined by FRS 102. The financial statements are prepared in sterling which is the functional currency of the charity and rounded to the nearest pound. There are no significant areas of judgements or key sources of estimation uncertainty.

#### GOING CONCERN

The Trustees as Directors of the Charity believe that there are no material uncertainties that may cast significant doubt about the ability of the Charity to continue as a going concern, due to the significant unrestricted reserves as at 31st December and the forecast income expected in 2024. As we prepare this statement in 2025, it is clear that the long tail of the COVID-19 pandemic, and its impact on the NHS workload, continues to have a bearing on the charity's operations, with applications for programmes such as fellowships and travel grants still low. It remains to be seen whether our events fundraising and income will be impacted by global issues such as the war in Ukraine and the current cost of living crisis, which may affect future budgets for research and training. The trustees believe, however, that given the level of available cash and reserves, the charity can continue as a going concern.

#### INCOME

Grants, donations and other similar types of voluntary income are brought into account when it is probable that they will be received, except that donated income is included gross of any attributable tax recoverable, where relevant. Donations given for specific purposes are treated as restricted income. Tax recoverable is recognised when claims are submitted to HM Revenue and Customs. Legacy gifts are recognised in the period in which the Charity becomes entitled to receive the income.

Income receivable from activities for generating funds and from investment income is accounted for on an accrual basis. Deferred income represents revenues collected but not earned as of 31 December 2024. This is primarily composed of income collected in advance of a fundraising event taking place and deferred until the charity is entitled to that income as and when the event takes place.

#### EXPENDITURE

Resources expended are allocated to the costs of generating funds or to the charity's principal activity where the costs can be identified as being directly related. All other costs are categorised as either support costs or governance costs and are allocated in proportions based upon a suitable ratio applicable to the nature of the cost involved.

Grants payable are recognised in full in the period in which the approved offer is conveyed to the recipient. Grants are recognised and deferred where there is a long-term commitment for the Charity. Where grants are recognised and conditions for staged grant payments are not met in subsequent years, an adjustment to grants payable will be made in the relevant accounting period. Expenditure includes irrecoverable VAT which is reported as part of the expenditure to which it relates.

## THE UROLOGY FOUNDATION

Financial statements for the year ended 31 December 2024

### ACCOUNTING POLICIES

---

#### TANGIBLE FIXED ASSETS

All tangible assets purchased that have an expected useful economic life that exceeds one year are capitalised and classified as fixed assets. Tangible fixed assets are stated at historical cost less depreciation. Depreciation is provided on all tangible fixed assets at rates calculated to write each asset down to its estimated residual value evenly over its expected useful life, as follows:

Office equipment	25% reducing balance
------------------	----------------------

#### OPERATING LEASES

Rentals under operating leases are charged to the Statement of financial activities on a straight-line basis over the lease term.

#### INVESTMENTS

The charity's investments are included in the balance sheet at their market value. The gains or losses arising upon their annual revaluation are included in the statement of financial activities.

#### FUND ACCOUNTING

The general fund comprises the accumulated surpluses of unrestricted incoming resources over resources expended, which are available for use in the furtherance of the general objective of the charity.

Designated funds are a particular form of unrestricted funds consisting of amounts, which have been allocated or designated for specific purposes by the trustees. The use of designated funds remains at the discretion of the trustees.

Restricted funds are funds subject to specific conditions imposed by donors. The purpose and use of the restricted funds are set out in the notes to the accounts. Amounts unspent at the year-end are carried forward in the balance sheet.

#### DEFINED BENEFIT PENSION SCHEME

The charity operates a defined contribution pension scheme. Contributions payable to the charity's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

#### DEBTORS

Trade debtors, other debtors and accrued income are recognised at the settlement amount due after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

#### CREDITORS

Creditors are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors are normally recognised at their settlement amount after allowing for any trade discounts due.

#### CASH AT BANK AND IN HAND

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

#### TAXATION

The charity is exempt from corporation tax on its charitable activities.



## **THE UROLOGY FOUNDATION**

**Financial statements for the year ended 31 December 2024**

### **ACCOUNTING POLICIES**

---

#### **FOREIGN EXCHANGE**

Receipts and payments which occur in foreign currencies are included in the accounts at the amount into which they are converted in sterling, using the exchange rate on the day in which the transaction occurs.

#### **FINANCIAL INSTRUMENTS**

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

	Unrestricted funds £	Restricted funds £	2024 £	2023 £
<b>1. INCOME FROM DONATIONS AND LEGACIES</b>				
Grants received from charitable trusts and corporate sponsors	99,494	1,004,752	1,104,246	1,238,227
Donations	186,971	-	186,971	136,210
Legacies	29,767	697,285	727,052	10,000
	<u>316,232</u>	<u>1,702,037</u>	<u>2,018,269</u>	<u>1,384,437</u>
<b>2. INCOME FROM OTHER TRADING ACTIVITIES</b>				
Income from fundraising events	<u>50,874</u>	<u>-</u>	<u>50,874</u>	<u>66,800</u>
<b>3. INVESTMENT INCOME</b>				
Bank interest receivable on short term cash deposits	3,753	-	3,753	4,996
Income from investments listed on a recognised stock exchange:				
UK investments	17,394	-	17,394	14,039
Overseas investments	-	-	-	-
	<u>21,147</u>	<u>-</u>	<u>21,147</u>	<u>19,035</u>
<b>4. COSTS OF RAISING FUNDS VOLUNTARY INCOME</b>				
Direct costs	5,931	30	5,961	5,812
Support costs (see note 8)	35,912	2,009	37,921	30,040
	<u>41,843</u>	<u>2,039</u>	<u>43,882</u>	<u>35,852</u>

THE UROLOGY FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS  
for the year ended 31 December 2024

	Unrestricted funds £	Restricted funds £	2024 £	2023 £
<b>5. COSTS OF RAISING FUNDS TRADING ACTIVITIES</b>				
Costs of fundraising events	10,289	-	10,289	7,276
Support costs (see note 8)	35,912	2,009	37,921	30,040
	<u>46,201</u>	<u>2,009</u>	<u>48,210</u>	<u>37,315</u>
<b>6. COSTS OF RAISING AWARENESS</b>				
Costs of fundraising events	24,007	-	24,007	16,976
Support costs (see note 8)	143,647	8,038	151,685	120,159
	<u>167,654</u>	<u>8,038</u>	<u>175,692</u>	<u>137,135</u>
<b>7. GRANT MAKING</b>				
	Unrestricted funds £	Restricted funds £	2024 £	2023 £
Innovation & Research Awards	10,570	516,939	527,509	435,592
TUF Trials Unit (TTU)	152,192	-	152,192	-
Championss Fund	-	-	-	143,304
David Thompson Fellowship	-	110,000	110,000	120,000
Small Research Projects awarded to 5 (2023: 6) teams	-	43,500	43,500	55,759
Education Bursaries and Grants	27,000	-	27,000	-
Prizes and awards	16,141	-	16,141	-
BAUN/TUF Nurse	14,391	-	14,391	6,100
Robotic Centres of Training	11,271	-	11,271	18,938
Other direct costs	7,357	272	7,629	26,001
Travel Grants	5,474	-	5,474	3,591
Strategic Funding	3,000	-	3,000	-
Urolink Fellowship	298	-	298	1,493
Burst	(9,996)	-	(9,996)	9,996
Keith Yeates medals awarded to 0 (2023: 1) individuals	(4,000)	-	(4,000)	1,415
BAUS	-	-	-	1,199
Research Scholarships awarded to 0 (2023: 0) individuals	-	-	-	(24,918)
Movement in present value of grant accruals	51,166	-	51,166	5,824
	<u>284,865</u>	<u>670,712</u>	<u>955,576</u>	<u>804,292</u>
Salary costs	-	104,511	104,511	53,495
Support costs (see note 8)	263,353	14,736	278,089	220,291
	<u>548,218</u>	<u>789,958</u>	<u>1,338,176</u>	<u>1,078,079</u>

# THE UROLOGY FOUNDATION

## NOTES TO THE FINANCIAL STATEMENTS for the year ended 31 December 2024

	Costs of generating voluntary income 7.5% £	Fundraising trading: Cost of goods sold 7.5% £	Awareness raising 30% £	Giving grants 55% £	2024 £	2023 £
<b>8. SUPPORT AND GOVERNANCE COSTS (UNRESTRICTED)</b>						
Staff costs (see note 9)	16,652	16,652	66,608	122,114	222,025	122,035
Other staff costs including recruitment	1,373	1,373	5,491	10,067	18,304	11,932
Committee and other staff welfare expenses	839	839	3,357	6,155	11,190	4,605
Other office costs	6,321	6,321	25,285	46,355	84,282	57,117
Audit fee	683	683	2,733	5,011	9,112	3,196
Accountancy and advisory services	1,759	1,759	7,037	12,902	23,458	13,738
Other costs	8,215	8,215	32,859	60,241	109,528	47,267
Depreciation-owned assets	69	69	277	508	924	513
	<u>35,912</u>	<u>35,912</u>	<u>143,647</u>	<u>263,353</u>	<u>478,823</u>	<u>260,403</u>
<b>8. SUPPORT AND GOVERNANCE COSTS (RESTRICTED)</b>						
Staff costs (see note 9)	887	887	3,549	6,507	11,831	39,851
Other staff costs including recruitment	74	74	294	540	981	3,896
Committee and other staff welfare expenses	45	45	180	330	600	1,504
Other office costs	428	428	1,714	3,142	5,713	73,742
Audit fee	37	37	147	269	488	1,044
Accountancy and advisory services	94	94	377	692	1,258	4,486
Other costs	440	440	1,762	3,230	5,872	15,435
Depreciation-owned assets	4	4	15	27	50	167
	<u>2,009</u>	<u>2,009</u>	<u>8,038</u>	<u>14,736</u>	<u>26,793</u>	<u>140,126</u>

**NOTES TO THE FINANCIAL STATEMENTS**  
**for the year ended 31 December 2024**

9. STAFF COSTS	2024	2023
	No.	No.
The average monthly number of persons employed by the charity (excluding trustees) during the period was, as follows:		
Office and administration	6.6	3.7
	£	£
Staff costs for the above persons:		
Wages and salaries	304,724	195,161
Social security costs	28,158	17,330
Employer's Contribution to Defined contribution Pension Scheme	5,484	2,891
	338,366	215,382

One employee received total emoluments in excess of £60,000 per annum during the period ended 31 December 2024 (2023: 1). The total emoluments of these employees during the year were in the following ranges:

**Key management personnel**

The remuneration of the key management personnel (including gross pay, employers' national insurance and employers pension contributions) was £104,051 (2023: £101,654).

	2024	2023
£90,000 - £100,000	No.	No.
	1	1

The Charity considers its key management personnel comprise the Chief Executive, with remuneration as noted above. In setting salary levels, The Urology Foundation follows the National Council for Voluntary Organisation's advice that a charity's pay policy should be to offer fair pay to attract and keep appropriately-qualified staff to lead, manage, support and/or deliver the charity's aims. It also conducts online research of charity salaries and uses surveys to benchmark levels of pay. The Urology Foundation does not automatically award its staff with annual salary increases, either incremental or cost of living.

No Director received any remuneration from the Company during the year (2023: £nil).

No trustee received any remuneration for services provided to the charity during the current or previous period.

Trustees expenses are included in note 20.

10. TANGIBLE ASSETS	Office Equipment £
Cost:	
1 January 2024	24,350
Additions	-
31 December 2024	24,350
Depreciation:	
1 January 2024	20,455
Charge for year	974
31 December 2024	21,429
Net book value:	
31 December 2024	2,921
31 December 2023	3,895

THE UROLOGY FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS  
for the year ended 31 December 2024

		2024 £	2023 £
<b>11.</b>	<b>INVESTMENTS</b>		
	Investments listed on a recognised stock exchange at market value:		
	1 January 2024	3,453,644	3,407,104
	Transfers from cash		
	Additions at cost	337,038	307,833
	Disposal proceeds	(319,643)	(551,126)
	Realised gains	-	3
	Unrealised (losses)/gains	166,523	289,830
	31 December 2024	<u>3,637,562</u>	<u>3,453,644</u>
	At the balance sheet date, the market value of the portfolio comprised:		
	UK investments	3,637,562	3,453,644
		<u>3,637,562</u>	<u>3,453,644</u>
	Fixed income securities	323,544	306,382
	Multi-Asset & Hybrid Instruments	3,314,018	3,147,262
		<u>3,637,562</u>	<u>3,453,644</u>
	At the balance sheet date, the historical cost of the investments was £2,718,286 (2023: £2,700,892). The following holdings had a value of >5% of the market value of the investments:		
		<b>Value £</b>	<b>Value £</b>
	<b>Name</b>	<b>2024</b>	<b>2023</b>
	<b>Holding</b>		
	Rothschild & Co WM SICAV-SIF Exbury Fund GBP	3,314,018	3,147,262
	Pentairs QIAIF PLC - Vanda Fund Shs -F- USD Shs		-
	InstitutionalCash SeriesPLC - BlackRock ICS Sterling Liquidity Fund	323,544	306,382
<b>12.</b>	<b>DEBTORS</b>	<b>2024 £</b>	<b>2023 £</b>
	Amounts falling due within one year:		
	Prepayments	17,348	18,978
	Accrued Income	<u>1,209,061</u>	<u>421,203</u>
		<u>1,226,409</u>	<u>440,181</u>

THE UROLOGY FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS  
for the year ended 31 December 2024

13.	CREDITORS	2024 £	2023 £
	Amounts falling due within one year:		
	Deferred income	959	13,382
	Trade creditors	150,239	150,500
	General accruals	11,939	7,183
	Grant accruals	611,010	795,272
	Other creditors	17,945	-
		<u>792,092</u>	<u>966,337</u>
	Deferred income b/fwd at 1 January 2024	13,382	
	Amounts released in the year	(13,382)	
	New amounts deferred in the year	959	
	Deferred income c/fwd at 31 December 2024	<u>959</u>	
	 CREDITORS	 2024 £	 2023 £
	Amounts falling due in more than one year:		
	Grant accruals	526,756	234,479
		<u>526,756</u>	<u>234,479</u>
14.	RECONCILIATION OF NET INCOME/(EXPENDITURE) TO NET CASHFLOW FROM OPERATING ACTIVITIES		
	Net Income/(expenditure) for the reporting period per the statement of financial activities	650,853	471,646
	Adjustments for:		
	Depreciation charges	974	680
	Gains on investments	(166,523)	(289,833)
	Dividends and interest from investments	(17,394)	(14,039)
	Management fees paid from investments	-	78
	(Increase)/Decrease in debtors	(786,229)	(26,732)
	Increase/(Decrease) in creditors	118,033	(304,721)
	Net cash used in operating activities	<u>(200,286)</u>	<u>(162,921)</u>



THE UROLOGY FOUNDATION

NOTES TO THE FINANCIAL STATEMENTS  
for the year ended 31 December 2024

15. THE FUNDS OF THE CHARITY

	1 January 2024 £	Transfer £	Income £	Expenditure £	Gains/(losses) on Investments £	31 December 2024 £
<b>Restricted income funds:</b>						
Robotic Surgery						
Training Fund	106,448	-	-	(22,500)	16	83,964
Prostate Cancer Research Fund	208,149	-	170,988	(181,558)	37	197,616
Champriss Fund	344,862	-	97,000	(25,345)	78	416,595
Team Corbs - Testicular	7,313	-	-	-	1	7,314
Charles Reynolds	13,002	-	-	(3,543)	2	9,461
Thompson Family Charitable Trust	126,556	-	300,000	(214,510)	40	212,086
Innovation & Research Awards	85,197	-	396,093	(343,841)	26	137,475
Small Research Projects	-	14,571	40,671	(10,748)	8	44,502
Events	6,839	-	-	-	1	6,840
Vivienne Irene Meader Scholarships	-	-	697,285	-	-	697,285
	898,366	14,571	1,702,037	(802,045)	209	1,813,138
<b>Unrestricted income funds:</b>						
General Fund	1,713,621	(1,064,571)	388,252	(803,915)	166,315	399,702
Designated Fund (BUF)	500,000	-	-	-	-	500,000
Research Strategy 2024-28 & Research Appeal	-	800,000	-	-	-	800,000
Infrastructure	-	250,000	-	-	-	250,000
	<u>3,111,987</u>	<u>-</u>	<u>2,090,289</u>	<u>(1,605,959)</u>	<u>166,523</u>	<u>3,762,840</u>

**RESTRICTED FUNDS**

Small Research Projects	The transfer from General Funds to Small Research Projects is to cover expenditure not externally funded in 2024.
-------------------------	---

**DESIGNATED FUNDS**

In September 2024 the Board of Trustees approved designated funds for the following purpose:

Research Strategy 2024-2028 and Research Appeal	A dedicated fund to support the new Research Strategy 2024-2028 and associated Research Appeal. The strategy is an exciting and ambitious plan to improve urology health and transform lives through research over the next five years. It builds on our history of clinical and academic innovation that has already helped to revolutionise urology care. Trustees have agreed to designate £1.5 million to enable the charity to achieve its long-term vision and mission. £800,000 of this is funded from designated unrestricted funds and £700,000 from a restricted legacy donation for scholarships.
Infrastructure	A dedicated fund of £250k to invest in the development of the charity's infrastructure including patient experience, campaigning, marketing, communications and to advance our fundraising capabilities to further diversify income and secure long-term sustainability.

## THE UROLOGY FOUNDATION

### NOTES TO THE FINANCIAL STATEMENTS for the year ended 31 December 2024

#### 15. THE FUNDS OF THE CHARITY (Continued)

##### THE FUNDS OF THE CHARITY (Full Fund Comparative)

	1 January 2023 £	Transfer £	Income £	Expenditure £	Gains/(losses) on Investments £	31 December 2023 £
<b>Restricted income funds:</b>						
Robotic Surgery Training Fund	160,170	-	-	(53,765)	43	106,448
Prostate Cancer Research Fund	137,269	-	45,879	24,918	84	208,149
Bladder Cancer Fund	184,851	-	359,000	(199,128)	139	344,862
Travel Fellowship Fund	648	-	-	(648)	0	0
Team Corbs - Testicular	7,311	-	-	-	3	7,313
Charles Reynolds	65,497	(52,500)	-	-	5	13,002
Thompson Family Charitable Trust	-	-	300,000	(173,495)	51	126,556
Innovation & Research Awards	-	72,500	491,614	(478,951)	34	85,197
Small Research Projects	-	51,456	11,000	(62,456)	0	0
Campaigns	-	(11,750)	11,750	-	0	0
Events	-	-	25,000	(18,164)	3	6,839
	<u>555,744</u>	<u>59,706</u>	<u>1,244,242</u>	<u>(961,689)</u>	<u>362</u>	<u>898,366</u>
<b>Unrestricted income funds:</b>						
General Fund	1,584,597	(59,706)	226,030	(326,771)	289,471	1,713,621
Designated Fund (BUF)	500,000	-	-	-	-	500,000
	<u>2,640,341</u>	<u>-</u>	<u>1,470,272</u>	<u>(1,288,460)</u>	<u>289,833</u>	<u>3,111,987</u>

- The Trustees have designated the original 1995 start-up funding for the BUF of £500,000 as the Trustees feel strongly that The Foundation should seek to maintain reserves sufficient to continue to fund its objectives on a long-term basis.
- The Robotic Surgery Training Fund was set up in 2009 following the receipt of restricted donation income from the British Urological Foundation and a generous private donation. The funds are mainly used to award grants towards robotically assisted surgery training, education, and research into robotic training techniques.
- Bladder Cancer Fund: Thanks to the generosity of the Champriss Foundation and the Champriss Charitable Trust, The Urology Foundation has been able to support a number of projects, including research projects tracking patients' fitness post cancer surgery and to predict complications arising during and post chemotherapy.
- Prostate Cancer Research - Thanks to the support of the John Black Charitable Foundation, The Urology Foundation has been able to support a number of projects furthering our understanding of prostate cancer and its treatments. Two further research grants were awarded in 2023.
- Team Corbs: The Foundation started working with former England and Lions rugby champion, Alex Corbisiero, to raise funds for research into testicular cancer, following Alex's diagnosis. A Just Giving page has been set up and the charity will continue to fundraise with Alex.
- Charles Reynolds funds are put towards supporting a number of our research projects and to support education and training for urology nurses, in particular through nurse bursaries and travel grants.
- The Thompson Family Charitable Trust generously support our charitable aims and objectives, in particular support of research and training, and through funding the David Thompson Fellowships. 2023 was in the inaugural year of the Fellowships and four awards were made.

## The Urology Foundation

### NOTES TO THE FINANCIAL STATEMENTS for the year ended 31 December 2024

#### 15. THE FUNDS OF THE CHARITY (Continued)

- **Innovation & Research Awards.** These are our key research awards, worth up to £60,000 per project to fund research and further our understanding into urological cancers and conditions.
- **Small Research projects.** These awards are primarily about studies that might improve patient pathways or treatment and care. Projects are worth £10,000 each.
- **Campaigns** - As part of the NHSE Cancer Programme's abdominal/urological "Help Us, Help You" symptoms awareness campaign and specifically the symptom "Blood in Pee", a series of community-based events were delivered across London. Visitors worried about a "blood in pee" symptom were encouraged to visit their GP or seek an early intervention.
- **Events** - The Foundation was pleased to receive support towards the TUF Trek to Namibia.

#### 16. ANALYSIS OF NET ASSETS BETWEEN FUNDS

As at 31 December 2024:	Unrestricted funds	Restricted funds	2024
	£	£	£
Fixed assets	2,921	-	2,921
Investments	1,895,719	1,741,843	3,637,562
Current assets	232,145	1,209,061	1,441,206
Current liabilities	(181,083)	(611,010)	(792,093)
Long Term Liabilities	-	(526,756)	(526,756)
	<u>1,949,702</u>	<u>1,813,138</u>	<u>3,762,840</u>

#### ANALYSIS OF NET ASSETS BETWEEN FUNDS (Full Fund Comparative)

As at 31 December 2023:	Unrestricted funds	Restricted funds	2023
	£	£	£
Fixed assets	3,895	-	3,895
Investments	1,946,730	1,506,914	3,453,644
Current assets	434,061	421,203	855,264
Current liabilities	(171,065)	(795,272)	(966,337)
Long term liabilities		(234,479)	(234,479)
	<u>2,213,621</u>	<u>898,366</u>	<u>3,111,987</u>

#### 17. CONTINGENT ASSETS

There were no contingent assets as at 31 December 2024.

#### 18. RELATED PARTY TRANSACTIONS

During the year, travel expenses amounting to £5,593 (2023: £2,257) were reimbursed to the Trustees. Donations of £240 (2023: £240) were received from the Trustees. No further transactions were undertaken such as are required to be disclosed under FRS 102 or the Charities Act.

#### 19. PENSION COMMITMENTS

The charity operates a defined contribution pension scheme. The costs for the period was £5,484 (2023: £2,891). Contributions amounting to £Nil were payable to the scheme at 31 December 2024 (2023: £Nil) and are included within creditors